Document:

EX-10.13

 

 
  

 Exhibit 10.13 

SERVICE AGREEMENT 
 FOR A
CLINICAL STUDY CONDUCT 
 concluded on 16 December 2013 (“Effective Date”) in Warsaw by and between: 

KCR S.A. (Polish joint-stock company) with its registered office in Warsaw at 6 Postępu Str., 02-676 Warsaw, Poland, entered in the register of
entrepreneurs kept by the District Court for the Capital City of Warsaw in Warsaw, 13th Commercial Division of the National Court Register, under number 0000289542, tax identification number NIP: 521-31-69-665, share capital (covered in total): PLN
700,000.00, hereinafter referred to as “CRO”, represented by Mr. Mike Jagielski – President of the Management Board and Ms. Anna Baran – Vice President of the Management Board, 

and 
 Vascular Biogenics Ltd., its principal place of
business at 6 Jonathan Netanyahu Street, Or Yehuda, Israel 60376 hereinafter referred to as “Sponsor”, represented by Prof. Dror Harats - Chief Executive Officer, 

hereinafter jointly referred to as „the Parties” and individually as a “Party”. 

Whereas: 
  

	 	a)	Sponsor intends to conduct a clinical study of the investigational medicinal product VB-201 [„Investigational Medicinal Product”] entitled “A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled
Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis” [„Study”] according to the protocol number VB-201-079 [“Protocol”] on the territory of Poland, 

 

	 	b)	Legal Representative of the Sponsor is SCIderm GmbH, a company organized and existing under the laws of Federal Republic of Germany, entered in the Trade Register maintained by the District Court in Hamburg, under the
number HRB 93824 with its registered office at Drehbahn 1-3, 20354 Hamburg, Germany, 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	 	c)	Sponsor wishes to engage CRO to provide services connected with the conduct of the Study as defined herein, 

  

	 	d)	fulfillment of CRO’s obligations resulting from this agreement is included in the scope of CRO’s business activity and CRO has an experience in providing services of similar nature as described herein,
including the fact that CRO employs qualified employees in order to perform such obligations. 

 Now then, the Parties agree to
conclude the agreement as follows [„Agreement”]: 
 § 1. Subject of the Agreement 

 

	1.	Sponsor hereby entrusts CRO with performance of activities connected with the conduct of the Study as defined in Attachment No. 1 hereto (Scope of Services), hereinafter referred to as „Services”, and CRO
hereby accepts such entrusted responsibilities. 

  

	2.	Services shall be performed within the timelines indicated in Attachment No. 2. Parties declare that these timelines shall be deemed as a forecast only and may be changed due to reasons which are not attributable
to the CRO. In case of necessity to provide Services within different timelines than those anticipated in Attachment No. 2 for reasons not attributable to CRO, Sponsor waives its right to bring any claims against CRO for an untimely provision
of Services. 

 § 2. Manner of Providing Services 

 

	1.	CRO shall perform its responsibilities, in the scope indicated in the Agreement, with due diligence and in compliance with laws and regulations in force applicable in the countries where the Services will be performed,
guidelines of Good Manufacturing Practice, Good Laboratory Practice, Good Clinical Practice, ICH GCP in a version applicable during the term of the Study conduct, in compliance with the Agreement and a valid version of the Protocol, constituting
Attachment No. 3 to the Agreement, CRO’s SOPs listed in Attachment No. 4 and any written instructions of the Sponsor. 

  

	2.	The CRO represents and warrants that it has obtained, and will maintain throughout the term of this Agreement, all governmental or regulatory approvals, licenses, registrations and insurances that may be required to
complete the Study, and that it has full right, power and authority to perform its obligations hereunder and to grant the rights set forth herein. During the term of this Agreement the CRO shall not conduct any other trial which, at the CRO’s
discretion, would adversely affect the ability of the CRO to perform their obligations under this Agreement. 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	3.	In order to perform Services, CRO undertakes an obligation to appoint from among its employees only persons with appropriate knowledge, experience and qualifications necessary to perform Services, and who have bound by
confidentiality undertakings according to this Agreement. 

  

	4.	The CRO certifies that it has not and will not use in any capacity in connection with this Agreement the services of any individual, corporation, partnership, or association which has been debarred, excluded, or
disqualified from participation in clinical investigations under any applicable laws, regulations, or guidance. In the event that the CRO receives notice of the debarment or threatened debarment, exclusion or disqualification or threatened
disqualification, of any individual, corporation, partnership or association providing services to the CRO, which relate to its activities under this Agreement, the CRO shall notify the Sponsor immediately. 

 

	5.	If the Sponsor raises any objections regarding provision of Services by a particular CRO employee, the Sponsor shall notify CRO of that fact in writing and may request replacement of such employee solely due to material
and reasonable objections against his/her work or behavior. CRO shall appoint a new employee with appropriate qualifications and experience in the shortest possible time. 

 

	6.	Sponsor shall have the right to reject any Services that it deems in nonconformance with the Protocol or the Agreement. Sponsor shall provide CRO with written notification of the deficiency or non-conformance and,
within thirty (30) days of receipt of such written notification, CRO shall correct the deficiency or non-conformance at CRO’s expense. 

  

	7.	During the term of the Agreement and subject to the prior approval of the Sponsor (e-mail form is acceptable), CRO may entrust a third party, such as sites, investigators, and other relevant sub-contractors
(“Sub-contractors”) with performance of all or some of the Services while observing due diligence in this choice, provided that such Sub-contractors are made aware of and acknowledge the obligations applicable to such Sub-contractors
according to this Agreement including without limitation confidentiality, Intellectual property rights and publications. The CRO shall ensure, and shall at all times remain jointly and severally responsible and liable, for the compliance of such
Sub-contractors with the terms of this Agreement. For the avoidance of doubt, the Parties agree that this section shall not release the Sponsor or the investigators from liability for the Study conduct according to provisions of law in force.

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	8.	CRO acknowledge that the Sponsor may entrust third parties with performance of services, which are related to the Study but are not included in the Services, which shall be provided by the CRO. A list of such third
parties attached hereto as Attachment 5 or as shall be amended by the Sponsor from time to time. CRO warrants that (i) it will fully cooperate with such third parties according to the Sponsor’s written instructions as necessary to the
conduct of the Study and (ii) it will be obligated by the relevant written instructions imposed by such third parties as shall be presented to the CRO by such third party or the Sponsor. 

 

	9.	CRO warrants that the assumptions underlying each Attachment and/or timeline have been arrived at in good faith by CRO, based upon its experience and professional judgment. In the event the CRO or Sponsor requests to
amend the Services, timelines or budget for a Study, the Parties agree to negotiate in good faith a written change order signed by the duly authorized representatives of the Parties. 

 

	10.	Both Sponsor and CRO shall carry, at its sole expense, with financially sound and reputable insurers, an insurance coverage with respect to the conduct of its business. 

§ 3. Sponsor’s responsibilities 

Sponsor undertakes an obligation in particular to: 
  

	 	a)	provide CRO with all information in its possession about the Investigational Medicinal Product necessary for the conduct of the Study, 

 

	 	b)	keep CRO informed on an ongoing basis about any new findings concerning safety of the Investigational Medicinal Product, 

  

	 	c)	supply CRO with the Investigational Medicinal Product manufactured in compliance with Good Manufacturing Practice, adequately packed and labeled, 

 

	 	d)	supply CRO with documentation necessary for conduct of the Study, including the valid version of the Protocol, Investigator’s Brochure and the Case Report Forms (CRF), 

 

	 	e)	conclude insurance agreement on third party liability of the Sponsor and investigators for damages related to the conduct of the Study, in compliance with laws in force and provide CRO with a valid copy of the insurance
policy confirming conclusion of such agreement, 

  

	 	f)	notify CRO immediately of any suspension of the Study or withdrawal of the approval for the conduct of the Study , 

  

	 	g)	perform other responsibilities not assigned to the CRO and necessary for the conduct of the Study. 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 § 4. Audits and inspections 

 

	1.	On Sponsor’s reasonable request, CRO shall, at any time, provide the Sponsor with information on the status of the Services performed. In particular, the Sponsor may request CRO to prepare an activity report on the
Services performed by CRO. 

  

	2.	During the term of the Agreement, CRO undertakes an obligation to allow the Sponsor and any competent authorities and national, foreign and international bodies or organizations responsible for registration of medicinal
products and supervision, audit or inspection of clinical studies to conduct an audit, control or inspection of the Study as well as to access the records related to the Study conduct, and to monitor and audit the activities of the
investigators and members of the study teams during the Study (including inspection and audit of the facilities and procedures used in the Study by the investigators and the study teams, as well as the equipment, data registration method and storing
the records), and to enable both Sponsor and any national, foreign and international bodies or organizations responsible for registration of medicinal products and supervision or inspection of clinical studies to obtain any and all information on
the conduct of the Study. 

  

	3.	CRO shall notify Sponsor if any competent authorities and national, foreign and international bodies or organizations responsible for registration of medicinal products and supervision, audit or inspection of clinical
studies inform CRO about any scheduled, or begin an unscheduled inspection of any study site, CRO or bioethics committee. CRO shall immediately provide the Sponsor with any correspondence and/or communication related to a notification, conduct and
results of an audit or inspection and shall inform the Sponsor of the measures to be taken following finding and recommendations of such inspection and audits and their results. 

 

	4.	Sponsor agrees to cover the costs of CRO’s employees involvement in an audit, control or inspection based on real time spent on such activities according to the rates described in Attachment No. 6.

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 § 5. Remuneration 

 

	1.	For execution of all obligations resulting from the Agreement by CRO, Sponsor undertakes an obligation to pay remuneration as well as reimburse costs and expenses as defined in net amounts in Attachment No. 6. Due
VAT shall be added to the above fee. 

  

	2.	The Sponsor is obliged to make payments within 30 days from the receipt of a VAT invoice from CRO and provided that the CRO has provided upon the execution of this Agreement a Certificate of Residency from its Tax
Authorities. If it is necessary to convert one currency into another, it shall be calculated by CRO on the basis of a current foreign exchange selling rate of the Polish National Bank announced on the date of the VAT invoice issuance.

  

	3.	The remuneration shall be calculated and paid on a monthly basis for the time committed to or a type of Services provided in a given month within 30 days from the delivery of the invoice issued by CRO to the Sponsor.
CRO shall be entitled to issue and deliver a VAT invoice beginning with the last day of a given month for the amount covering time or type of Services performed in such month. 

 

	4.	On Sponsor’s request, CRO shall submit a list of Services performed in a given month, including a timesheet of persons providing Services with a detailed description of activities performed. 

 

	5.	The Sponsor shall reimburse CRO: 

  

	 	a)	for any costs incurred by CRO in connection with conclusion of the Agreement and providing the Services hereunder - so called “pass through costs”, including in particular costs of telephone connections,
faxes, internet, courier and mail services, accommodation and travel expenses of persons appointed to perform Services, which will be incurred in connection with the execution of the Agreement. These expenses will be invoiced on a monthly basis and
presented to the Sponsor with a detailed list. 

  

	 	b)	for any costs related to use of CRO company cars for business travels to and from study sites indicated by the Sponsor, 

  

	 	c)	for any other costs necessary for the proper conduct of the Study provided that such expenses have been pre-approved by the Sponsor. 

 

	6.	Specification of expected costs and expenses (so called „pass through costs”) is included in Attachment No. 6 hereto. In case if costs, expenses or a scope of Services connected with the conduct of the
Study appear to be higher than those anticipated on the Agreement date, the Sponsor undertakes an obligation to cover these costs and reimburse CRO for expenses incurred in relation to the execution of the Agreement provided that such expenses have
been pre-approved by the Sponsor. 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	7.	When CRO is in charge of investigators, sites, Study subject or IRB/EC fees or expenses payment or reimbursement, estimated or known amounts for such payments/reimbursements will be invoiced to the Sponsor, before
paying such fees or expenses. The CRO has no obligation to advance funds and make these payments unless and until the funds are received from the Sponsor. If Sponsor does not provide funds in time to enable CRO to make timely payments, Sponsor
agrees to be liable for and to reimburse CRO for any interest and other charges, costs, fees and expenses incurred by CRO because of such late payment. Any excess funds paid to CRO for such fees and expenses shall be refunded to Sponsor at the end
of the Study or sooner, upon Sponsor’s request. 

  

	8.	Sponsor is obliged to reimburse CRO for the costs and expenses incurred by CRO in relation to the execution of the Agreement within 30 days from the receipt of relevant documentary evidence supporting such costs and
expenses from CRO. 

  

	9.	Payment of the remuneration and reimbursement of costs incurred by CRO shall be made by a transfer to CRO bank account indicated on the invoice. 

 

	10.	CRO rates included in the budget in Attachment 6 shall automatically increase each calendar year beginning from January 1, 2015 for the next 12 month period, according to year inflation rate published by Eurostat,
the Statistical Office of the European Communities. The Parties agree that increase of rates shall be effective from the beginning of calendar year regardless of the date of publishing year inflation rate by Eurostat. 

§ 6. Confidentiality 
  

	1.	The CRO shall keep confidential any and all information and data concerning Sponsor`s business or its activities (including reports and information as well as all clinical data about the Study or its progress produced
by the CRO or the sites within the framework of this Agreement), or information obtained that may come to the knowledge of the CRO, its personnel or appointed representatives during or in connection with the execution of this Agreement including
without limitation third party confidential information received by the Sponsor (“Sponsor’s Confidential Information”). For the avoidance of any doubt, the Protocol, the Investigational Medicinal Product, the Study results, and the
Inventions (as defined below) shall be considered the Sponsor’s Confidential Information. 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	2.	Sponsor shall keep confidential any and all information and data concerning the CRO`s business or its activities (including information produced by Sponsor within the framework of this Agreement) or information obtained
that may come to the knowledge of Sponsor, its personnel or appointed representatives during or in connection with the execution of this Agreement, and is not considered Sponsor’s Confidential Information. 

 

	3.	Parties undertake an obligation to keep strictly confidential any confidential information or data which came into possession of the other Party in any manner, were delivered or otherwise disclosed to the other Party in
connection with the Agreement. Parties may use and make the above mentioned information available solely for the purpose of the execution of the Agreement. 

  

	4.	The above provision does not apply to information which the receiving Party can demonstrate that: 

  

	 	a)	is known to the receiving Party at the moment of its disclosure, 

  

	 	b)	is publicly accessible at the time of its disclosure to the receiving Party or it becomes later publicly accessible without the Party’s fault, 

 

	 	c)	may be disclosed upon the other Party’s consent expressed in writing otherwise being void, 

  

	 	d)	was disclosed to the receiving Party by a third party that was not obliged to keep it confidential or 

  

	 	e)	is disclosed by virtue of laws in force. 

  

	5.	If confidential information needs to be disclosed to a third party for the purpose of performance hereof, the Sponsor or CRO, prior to making any such disclosure, will cause such third party to undertake the
confidentiality and non-use obligations in writing at least to the extent applicable to themselves under the Agreement. Any publication of data from the Study or oral presentations on an individual basis with respect to the Study data shall be
subject to the Sponsor’s prior review and approval. The Sponsor is entitled at its sole discretion to delay or reject of such publication due to Sponsor’s business or operational reasons. 

§ 7. Personal data processing 
  

	1.	 Sponsor undertakes to observe the provisions of Personal Data Protection Act of 29th of August 1997 (uniform text: Journal of Laws from 2002,
No. 101, position 926 with later changes) as well as secondary regulations, regarding personal data of CRO’s employees, contractors and other individuals (such as employees of CRO’s contractors), provided by CRO to Sponsor, in

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	 	
the scope of performance the obligations under the Agreement. The personal data of the CRO’s employees, contractors and other individuals will be processed by Sponsor on grounds of their
consent or justified purposes of a data controller. However, for the purposes of processing by Sponsor of the personal data of the CRO’s employees or contractors in relation to the execution of obligations of CRO as an employer, CRO entrusts
Sponsor with the processing of such personal data in accordance with the Agreement. 

  

	2.	Sponsor appoints CRO as its representative within the meaning of article 31a of the Personal Data Protection Act. 

  

	3.	The scope of the entrusted personal data includes the following categories: names, surnames, addresses, contact details, professional experience, current and past position, education, skills. Sponsor undertakes to
process the personal data by collecting, recording, storing, deleting compiling, amending, transferring in paper form and by electronic means. 

  

	4.	Sponsor cannot use entrusted personal data for any other purpose or in any other manner than necessary to execute the Agreement. Sponsor is also obliged neither to disclose nor to pass on the personal data to any entity
without prior written CRO’s consent. 

  

	5.	Sponsor is liable for the damages caused to CRO or any third party in the result of personal data processing against the Agreement by Sponsor or under its responsibility. 

 

	6.	When the Agreement is finished/terminated/expired, Sponsor is obliged to finish personal data processing, return or destroy all received documents and their copies, and return all received electronic data mediums to
CRO. 

  

	7.	Sponsor entrusts CRO with the processing of personal data of the investigators and the members of study teams for the purposes of the performance of activities connected with the conduct of the Study. The scope of the
entrusted personal data includes the following categories: names, surnames, addresses, place of work, telephone numbers, e-mail addresses, bank account numbers, PESEL numbers, tax identification numbers, professional experience, current and past
position, education. CRO undertakes to process the personal data by collecting, recording, storing, deleting, compiling, amending, transferring in paper form and by electronic means. Sponsor hereby authorizes CRO to subcontract the processing of the
personal data to a further data processor as shall be agreed in advance by the Sponsor. 

  

	8.	CRO undertakes to observe the provisions of the Personal Data Protection Act and the secondary regulations. CRO cannot use the entrusted personal data for any other purpose or in any other manner than necessary to
execute the Agreement. 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	9.	In relations between CRO and Sponsor acting as data controllers / data processors towards each other, the following rules shall apply accordingly: 

 

	 	a)	the data processor is hereby obliged, prior to commencing the processing of the personal data and afterwards, during the term of this Agreement, to apply any technical and organizational measures that will ensure the
security of the personal data being processed, as set forth in the Personal Data Protection Act and the secondary regulations, and any legislation that will supplement and/or replace them in the future; in particular, it should secure the personal
data against access by unauthorized persons, its removal by unauthorized persons, and against it being damaged or destroyed; 

  

	 	b)	the data processor shall be obliged to ensure supervision of the following: when and by whom the personal data has been entered into the data filing system and to whom the data has been transferred; 

 

	 	c)	the data processor undertakes to preserve the confidentiality of the personal data entrusted to it under this Agreement; 

  

	 	d)	only persons who were authorized by the data processor shall be allowed to carry out the processing of personal data; 

  

	 	e)	the data processor shall be obliged to take all necessary steps to ensure that the persons referred to in point (d) of this clause keep the personal data and the methods of their protection confidential;

  

	 	f)	the data processor shall immediately inform the data controller of any instance of any breach, whatsoever, of the security of the personal data entrusted to the data processor and processed under this Agreement;

  

	 	g)	the data processor shall grant the data controller, at its request, any necessary information concerning all personal data processed by the data processor; 

 

	 	h)	the data controller shall have the right to conduct inspections as to whether the data processor is observing the principles of processing the personal data specified in the Personal Data Protection Act, the secondary
regulations and this Agreement, by accessing and inspecting any premises where the personal data is processed, as well as the documents, equipment and IT systems relating to the personal data processing; 

 

	 	i)	the data controller shall be entitled to review whether the above principles of the processing of the personal data are being observed and as such the data controller’s representatives will be entitled to demand
that the data processor’s representatives provide to the data controller the necessary information concerning the way in which the data processor processes the personal data contained in the data filing system; 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	 	j)	any inspection of whether the above principles of the personal data processing are being observed may only take place after the data controller has notified the data processor of the intention of carrying out such an
inspection at least two days in advance of the date of the commencement of the inspection, and has indicated in writing the persons designated to carry out the inspection; an inspection may be exercised by the data controller at the location where
the personal data are being processed – between the hours of 9 a.m. and 4 p.m. on any business day; 

  

	 	k)	following the inspection, the data controller may draw up recommendations concerning the improvement of the quality of the safeguarding of the personal data, as well as the means of its processing by the data processor
and the means of remedying any identified irregularities, which the data processor is obliged to immediately remedy not later than 30 days after the data controller’s notification of its observations; 

 

	 	l)	upon the expiry or termination of this Agreement the data processor shall be obliged to transfer the personal data to the data controller or delete all the personal data, within seven days of receiving the data
controller’s instruction; the deletion of the personal data shall be understood as the erasing of the personal data, or their modification in such a way that the identity of the persons to whom the data refers cannot be established.

 § 8. Intellectual property 
  

	1.	The Parties acknowledge that all rights to materials, Investigational Medicinal Product, data bases, notes, analyses, lists, studies or any other documents, as well as names and graphic signs made available to CRO by
the Sponsor in any manner whatsoever, shall remain the property of the Sponsor and CRO shall not acquire any rights thereto, except for the right of use thereof during execution of the Agreement for the purpose of conducting the Study in the manner
permitted by the Sponsor. 

  

	2.	Inventions or discoveries whether or not patentable, processes, trade secrets, data, improvements, and/or patents relating to the Investigational Medicinal Product or otherwise arising from the Study, conceived,
generated, developed or first reduced to practice, as the case may be, during the term of this Agreement (hereinafter called “Inventions”), either by the CRO, its employees, sites, investigator or any other Sub-contractors related to this
Agreement shall be the property of the Sponsor. 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	3.	The CRO its employees, sites, investigator or any other Sub-contractors will promptly inform Sponsor of any Invention or discovery arising from the Study, and assign its rights in relation to all intellectual property
rights and know how, and provide reasonable assistance to the Sponsor in filing or prosecuting intellectual property rights, at the expense of the Sponsor. 

§ 9. Duration of the Agreement and its termination 
  

	1.	The Agreement is concluded for a specified period of time and shall be valid from the Effective Date until the termination of the Study unless any circumstances indicated below should occur. 

 

	2.	Each Party has a right to terminate the Agreement with immediate effect in case of a material breach by the other Party of the obligations resulting from the Agreement if a default is not cured within 30 (thirty) days
from the date of delivery of a written notice on the discovered breach to the other Party. 

  

	3.	The Sponsor has a right to terminate the Agreement upon 90 days’ written notice without giving cause and CRO has a right to terminate the Agreement upon 120 days’ written notice without giving cause.

  

	4.	Upon receipt of the notice of termination of the Agreement from the Sponsor by CRO or dispatch of the same to the Sponsor by CRO, CRO shall make all possible efforts to terminate or transfer further conduct of any
unfinished Services as soon as possible, according to the Sponsor’s instructions. In such a case, CRO shall cease to provide Services or undertake further obligations in connection with the Services unless Parties agreed otherwise in writing.

  

	5.	The Sponsor undertakes an obligation to reimburse CRO for all necessary and actual costs connected with the termination or expiration of the Agreement as well as to pay CRO due remuneration, in particular to reimburse
CRO for any expenses incurred (so called „pass through costs”) or to be incurred in relation to provision of the Services from which CRO cannot withdraw. Promptly after the date of the Agreement termination or expiration, CRO shall issue
an invoice for the above costs and expenses to the Sponsor. 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 § 10. Non-Solicitation Clause 

 

	1.	The Sponsor undertakes an obligation that it shall not employ any employee of the CRO , in its own enterprise or in any company under its control, during the term of the Agreement and for the period of 2 years from the
date of termination or expiry hereof. 

  

	2.	In the event of employing the above mentioned persons, the Sponsor shall be obliged to pay a contractual fine in the amount of Euro 50 000 (say: fifty thousands) per each person employed within 7 days from the receipt
of the call for payment. Payment of contractual fine shall not deprive CRO of its right to claim damages exceeding the amount of the contractual fine reserved. 

§ 11. Final provisions 
  

	1.	Neither Party shall be liable to the other Party in connection with this Agreement for any indirect, consequential (including without limitation lost profits), incidental, special or punitive damages. 

 

	2.	CRO shall not bear any liability connected with the Investigational Medicinal Product, including liability for administering the Investigational Medicinal Product. CRO’s liability due to negligence, non-adherence
to professional standards or breach of the Agreement shall be limited to the double amount of the remuneration (CRO fee) received. 

  

	3.	Sponsor shall defend, indemnify, and hold harmless CRO, its affiliates and their respective directors, officers, employees, consultants, sub-contractors, independent contractors, and agents from and against any and all
losses, claims (including third party claims), actions, damages, liabilities, awards, costs and expenses (including reasonable legal counsel fees and expenses), whether joint or several, relating to or arising from or in connection with this
Agreement or the Services contemplated herein, including but not limited to, the Study, test, specifications, compound, device, placebo or Investigational Medicinal Product, potential product or procedure performed or administered as a result of the
Protocol and this Agreement or any litigation, investigation or other proceeding relating to any of the foregoing, unless as a result of CRO’s its affiliates and their respective directors, officers, employees, consultants, sub-contractors,
independent contractors, and agents negligence, non-adherence to professional standards or breach of the Agreement. 

  

	4.	 CRO shall defend, indemnify, and hold harmless Sponsor, its affiliates and its and their respective directors, officers, employees, and agents from
and against any and all losses, claims (including third party claims), actions, damages, liabilities, costs and expenses (including 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	 	
reasonable legal counsel fees and expenses) (“Sponsor Losses”) but only to the extent such Sponsor Losses are related to or arise from or in connection with CRO’s negligence,
non-adherence to professional standards or breach of this Agreement, except to the extent that such Sponsor Losses arise from (i) the negligence or reckless or willful act or omission of Sponsor, its affiliates or its and their respective
directors, officers, employees, contractors or agents; or (ii) any breach of this Agreement by Sponsor, its affiliates, or its and their respective directors, officers, employees, contractors or agents. 

 

	5.	The Party seeking indemnity will give the indemnifying party prompt written notice (within 15 days knowledge) of any matter upon which such indemnified party intends to base a claim for indemnification (an
“Indemnity Claim”). The indemnified party shall have the right to participate jointly with the indemnifying party, at its own expense, in the defense, settlement or other disposition of any Indemnity Claim. 

 

	6.	In no event shall either Party be liable to the other in case of not being able to perform its obligations hereunder due to a natural disaster, general strike, war, riots, fire, order of the authorities or any other
unforeseeable and unpreventable circumstances, provided that such Party unable to perform its obligation will do its best effort to fulfill its obligations. The Party affected by such circumstances shall immediately notify the other Party of this
fact in writing, providing any relevant information regarding the matter. 

  

	7.	No Party may assign any rights or obligations resulting from the Agreement to any third party without prior written consent of the other Party. 

 

	8.	Any representations of the Parties as specified herein shall be made in writing, otherwise null and void. 

  

	9.	Except for cases expressly indicated in the Agreement, all statements, notices, calls etc. connected with the Agreement must be delivered to the addresses of the Parties defined in the preamble hereof, otherwise void
and ineffective. Either Party should notify the other of the change of its address in accordance with this paragraph. Such notice shall be deemed properly served by the Party after its receipt by the addressee. All and any notices and statements
sent thus far in connection with this Agreement to the addresses given above shall be deemed as served effectively. 

  

	10.	Provisions of § 4, § 6, § 8 and § 10 of the Agreement shall remain in force despite its expiry or termination for any reason. 

 

	11.	For the avoidance of doubt, this Agreement and the Protocol may only be amended by the agreement in writing of duly authorized signatories of Sponsor and CRO, otherwise being null and void. Changes in the Protocol may
imply changes in the total course of the Study (costs, time-lines etc.). 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

	12.	If any one or more provisions of this Agreement shall be found to be illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or
impaired thereby. 

  

	13.	The Agreement and any matters connected herewith shall be governed by the laws of England, excluding its rules for choice of law. Any dispute relating to or arising in connection with this Agreement, which is not
settled within a reasonable time, shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce (“ICC”) by one arbitrator appointed in accordance with the said rules. The award shall be final and binding
and enforceable in any court of competent jurisdiction. The arbitration shall be held in London, United Kingdom, in English language. 

  

	14.	The Agreement has been drawn up in two identical counterparts, one counterpart for each of the Parties. 

  

			
	CRO:	  	Sponsor:
		
	 Anna Baran /s/ Anna Baran
  

Mike Jagielski /s/ Mike Jagielski
	  	 /s/ Amos Ron
 Vascular Biogenics Ltd.

Amos Ron, CFO
 January 1, 2014

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 Attachment No. 1 

Scope of Services: 

Part A 
 Study
Assumptions 
 STUDY ASSUMPTIONS 
  

			
	 
	Number of countries involved	  	1
	COUNTRIES INVOLVED	  	Poland
	CRA staff involved	  	3
	STUDY SITES	  	10
	PATIENTS ENROLLED (# of expected)	  	50
	NUMBER OF PATIENT’s VISITs IN SITE DURING THE STUDY	  	9
	PLANNED NUMBER OF PAYMENTS FOR PI AND SITES DURING THE STUDY	  	3

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 Attachment No. 1 

Scope of Services: 

Part B 
 Division of
Responsibilities CRO - Sponsor 
  

							
	 	  	KCR	  	VBL
Ltd.	  	 Comments

	STUDY INITIATION	  		  		  	
				
	Protocol development	  		  	X	  	
				
	Protocol review	  	X	  	X	  	KCR to review the draft of study protocol and provide VBL with comments.
				
	Protocol approval	  		  	X	  	
				
	Protocol printing	  	X	  		  	
				
	Protocol distribution to sites	  	X	  		  	
				
	Preparation of amendments	  		  	X	  	
				
	CRF design and development (e CRF)	  		  	X	  	
				
	CRF review & approval	  		  	X	  	
				
	Preparation of master Informed Consent (IC) and Patient Information Sheet (PIS)	  		  	X	  	
				
	Revision and translation of Informed Consent and Patient Information Sheet according to local Ethical Committee requirements	  	X	  		  	
				
	Final approval of country specific IC and PIS	  		  	X	  	Based on back translation of local of Informed Consent and Patient Information Sheet. Approval process according to KCR SOP.
				
	Monitoring Plan development	  	X	  		  	
				
	Monitoring Plan approval	  		  	X	  	
				
	Recruitment Plan development	  	X	  		  	
				
	Trial Master File Set-up	  	X	  		  	
				
	Distribution of Site Documents	  	X	  		  	
				
	Randomization schedule preparation	  	X	  		  	
				
	REGULATORY / ETHICS COMMITTEE SUBMISSIONS	  		  		  	
				
	Preparation of the documentation for Ethics Committees	  	X	  	X	  	 VBL to provide:
 - Investigator’s
Brochure
 - IMPD
 - CRF

- Insurance certificate
 - Patient related scales/diaries

- Certificate of analysis
 - Drug label

- Manufacturing authorisation
 - GMP certificate 

KCR to provide VBL with country specific requirements regarding submission and to prepare submission
package.

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

							
	 	  	KCR	  	VBL
Ltd.	  	 Comments

				
	Submission of the documentation for Ethics Committees and follow up until authorisation	  	X	  		  	
				
	Preparation of the documentation for Regulatory Authorities	  	X	  	X	  	 VBL to provide:
 - Investigator’s
Brochure
 - IMPD
 - CRF

- Insurance certificate
 - Patient rated

scales/diaries - Certificate of analysis

				
		  	X	  	X	  	 - Drug label
 - Manufacturing authorisation

- GMP certificate
 KCR to provide VBL with country specific
requirements regarding submission and to prepare submission package.

				
	Submission of the documentation for Regulatory Authorities and follow up until authorisation	  	X	  		  	
				
	TRANSLATIONS	  		  		  	
				
	Translations	  	X	  		  	Relevant for patient-related documents, labels, Power of Attorney
				
	SITE RECRUITMENT AND INITIATION	  		  		  	
				
	Investigator’s Site Identification	  	X	  		  	
				
	Investigator’s Site Selection	  	X	  		  	
				
	Final Site Selection	  	X	  	X	  	 KCR to provide VBL with pre-study visit reports and lists of recommended sites in all selected countries.

VBL to approve selected sites.

				
	Conduct Site Selection Visits	  	X	  		  	
				
	Negotiate Investigators/Sites Contracts	  	X	  		  	
				
	Final Approval for Investigators/Sites Contracts	  		  	X	  	
				
	Signature on Investigators/Sites Contracts	  	X	  		  	
				
	Regulatory Documents collection & review	  	X	  		  	
				
	Conduct Site Initiation Visits	  	X	  		  	
				
	INVESTIGATOR MEETING	  		  		  	
				
	Investigator’s Meeting Planning	  	X	  		  	
				
	Investigator ‘s Meeting Preparation	  	X	  	X	  	 VBL to present:
 -VB-201: Scientific
Background
 -Phase I/II Experience & Development Plan

-Study Design & Objectives
 -Protocol Overview

-Eligibility Criteria
 -Study Specific Procedures

-Study Assessment Scales KCR to present:
 -Communication Plan

-Timelines & Recruitment Strategies
 -ICH GCP
Refreshment

				
	Investigator’s Meeting Attendance	  	X	  	X	  	
				
	STUDY DRUG MANAGEMENT/ CENTRAL LABORATORY MANAGEMENT	  		  		  	
				
	Clinical Trial Supply Logistics Management	  		  	X	  	
				
	Packaging and labeling of study medication	  		  	X	  	
				
	Distribution of study medication to sites	  		  	X	  	
				
	Destruction of unused supplies	  		  	X	  	
				
	Randomization list management	  		  	X	  	
				
	Central Laboratory Supplies and Logistic Set-up/Courier Management	  		  	X	  	By VBL subcontractor.
				
	Central Laboratory Management	  		  	X	  	VBL subcontractor to manage the central laboratory.
				
	STUDY MONITORING	  		  		  	
				
	Conduct Site Monitoring Visits	  	X	  		  	
				
	Communication with Sites	  	X	  		  	
				
	Monitoring visit reports preparation and review	  	X	  		  	
				
	Monitoring visit reports final approval	  		  	X	  	
				
	S.D.V.: (100% of patients, 100% of key study parameters)	  	X	  		  	
				
	Periodic Regulatory Document Collection / Updates (Investigator’s Master File management)	  	X	  		  	
				
	Data review/correction on all CRF’s	  	X	  		  	
				
	Resolution of Queries with Sites	  	X	  		  	

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

							
	 	  	KCR	  	VBL
Ltd.	  	 Comments

	SAE Reconciliation with Sites	  	X	  		  	
				
	Conduct Site Close-out / Termination Visits	  	X	  		  	
				
	Drug accountability during study and final drug record reconciliation	  	X	  		  	
				
	End of Study Notification to Regulatory Agencies/ECs	  	X	  		  	
				
	CLINICAL STUDY MANAGEMENT	  		  		  	
				
	Maintain Central Trial Master File	  	X	  		  	
				
	Fortnightly enrolment updates and Weekly Status Reports to Sponsor	  	X	  		  	
				
	Administered Investigator’s Payments	  	X	  		  	KCR will be responsible for bank transfers.
				
	Prepare and Distribute Newsletter (if applicable)	  		  	X	  	
				
	Central File Archiving	  		  	X	  	
				
	Clinical Team Communication	  	X	  		  	KCR to provide Communication Plan.
				
	MEDICAL MONITORING	  		  		  	
				
	Development of Medical Monitoring Plan	  		  	X	  	
				
	Provide Medical Oversight to CRO Project Team	  		  	X	  	
				
	Medical Communication/Consultation with Sites	  		  	X	  	
				
	Patient Eligibility - Medical Review	  		  	X	  	
				
	Review Safety Data Listing	  		  	X	  	
				
	Review CRFs for safety/efficacy	  		  	X	  	
				
	Review Safety Laboratory Data	  		  	X	  	
				
	Review of Data Management Coding	  		  	X	  	
				
	Review of Data Management SAE reconciliation	  		  	X	  	
				
	Organization of Data Safety Monitoring Board Meeting	  		  	X	  	
				
	SAFETY MONITORING	  		  		  	
				
	Safety Plan Preparation	  		  	X	  	
				
	SAE Reporting Procedure and Database Set-up	  		  	X	  	
				
	Receipt & Review of Initial SAE Report from Site	  	X	  		  	
				
	Tracking /Analyzing SAE Report	  		  	X	  	
				
	Entering SAE into Database	  		  	X	  	
				
	Writing SAE Narrative	  		  	X	  	
				
	Expectedness Judgment for SAE & Regulatory Reporting Assessment	  		  	X	  	
				
	Final Medical and Regulatory Judgment	  		  	X	  	
				
	Preparing Annual Report for Competent Authority in EU (inc. safety update)	  		  	X	  	
				
	Reporting Expedited SAEs to Regulatory Authorities	  		  	X	  	
				
	Reporting Expedited SAEs to Investigators and EC	  	X	  		  	
				
	Ongoing SAE File Maintenance	  		  	X	  	
				
	DATA MANAGEMENT	  		  		  	
				
	Preparation of Data Management Documentation such as Data Management Plan, Data Review Plan, Data Handling Guiding	  		  	X	  	
				
	EDC collector development	  		  	X	  	
				
	Data Review, Query Generation	  		  	X	  	
				
	Query Resolution	  	X	  		  	
				
	Import of Electronic (Laboratory) Data	  		  	X	  	By VBL subcontractor
				
	Reconciliation of SAEs	  		  	X	  	
				
	Provision of data extracts during study to support interim analyses	  		  	X	  	
				
	Documentation Maintenance	  		  	X	  	
				
	Archiving of EDC tool, Archiving of Data Management Material	  		  	X	  	
				
	STATISTICS AND REPORTING	  		  		  	
				
	Development of Statistical Analysis Plan	  		  	X	  	
				
	Final Approval for Statistical Analysis Plan	  		  	X	  	
				
	Creation of Analysis Dataset (Statistical analysis of the dataset)	  		  	X	  	
				
	Programming of Tables, Figures and Listings	  		  	X	  	
				
	PK parameters calculation	  		  	X	  	

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

							
	 	  	KCR	  	VBL
Ltd.	  	 Comments

	Development of interim and final Integrated Statistical/Clinical Report in conformity to ICH guideline and CTD	  		  	X	  	
				
	Review of final Integrated Statistical/Clinical Report in conformity to ICH guideline and CTD	  		  	X	  	
				
	Final Approval for clinical Study Report	  		  	X	  	
				
	Writing of SAE and AE Discontinuation Narratives	  		  	X	  	
				
	AUDITS	  		  		  	
				
	Conduct of GCP Audits of Investigator’s Sites	  	X	  		  	
				
	Conduct of Quality Assurance Audit of Database	  		  	X	  	
				
	PROJECT MANAGEMENT	  		  		  	
				
	Management of the study team	  	X	  		  	
				
	Communication with study sponsor and vendors	  	X	  		  	
				
	Coordination of start-up activities, realization phase and closure	  	X	  		  	
				
	Oversees the regulatory document collection and submission process.	  	X	  		  	
				
	Control and track the budget monthly and cumulative realization	  	X	  		  	
				
	Preparation of Risk Management Plan and/or Contingency Plan, if required	  	X	  		  	
				
	CONTRACTS AND PAYMENTS	  		  		  	
				
	Preparation of study contracts	  	X	  		  	
				
	Signature and payments	  	X	  	X	  	
				
	Payment of Ethics Committees’ fees	  	X	  		  	

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 [***] 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 [***] 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

			
	Protocol VB-201-079	  	VB-201

 CLINICAL PROTOCOL 
  

	 Title: 
	A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis 

 

	 Protocol No. 
	VB-201-079 

  

	 Eudra CT No.: 
	2012-002763-10 

  

	 Investigational Product: 
	VB-201 

  

	 Indication: 
	Plaque Psoriasis 

  

	 Development Phase: 
	2 

  

	 Sponsor: 
	Vascular Biogenics Ltd. 

 6 Jonathan Netanyahu St. 

Or Yehuda, Israel 60376 

Phone: 972-3-6346450 

Fax: 972-3-6346449 
  

	 Version: 
	2.2 (Poland and Israel only) 

  

	 Date: 
	December 2, 2013 

 CONFIDENTIAL 

This document contains proprietary and confidential information of VBL. Acceptance of this document constitutes agreement by the recipient that no previously
unpublished information contained herein will be published or disclosed without the prior written approval of Vascular Biogenics Limited with the exception that this document may be disclosed to study personnel under your supervision who need to
know the contents for conducting the study and appropriate Institutional Review Boards (IRBs)ZEthics Committees (1EC) under the condition that the personnel have agreed to keep this information confidential. The foregoing shall not apply to
disclosure required by governmental regulations or laws, however, VBL shall be promptly notified of any such disclosure. 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 Attachment No. 4 

List of SOPs applicable for the Study conduct 

KCR SOP AND ASSOCIATED FORMS AND TEMPLATES 
  

					
	 
	 	  	Version	  	Effective date
	 101.1 MED. Feasibility process
	  	5	  	06 Dec 11
	  
 Associated Forms And
Templates:
 101.1 MED. 01 Short Feasibility Worksheet
	  	2	  	08 Mar 10
	 101.1 MED. 02 Feasibility Questionnaire
	  	3	  	06 Dec 11
	 101.1 MED. 03 Feasibility Results
	  	2	  	08 Mar 10
	 101.1 MED. 04 Thank You Letter
	  	1	  	06 Dec 11
			
	 102.1 MED. Regulatory Submission for Clinical Study Application
	  	4	  	13 Dec 12
			
	 102.3 MED. Updating Clinical Study Documentation
	  	2	  	13 Aug 12
			
	 102.5 MED. Management of Regulatory Process
	  	2	  	13 Aug 12
			
	 103.1 MED. Pre-Study Visit
	  	2	  	21 Feb 11
			
	 Associated Forms And Templates:
	  		  	
	 103.1 MED. 01 Confirmation Pre-study Letter
	  	2	  	21 Feb 11
	 103.1 MED. 02 Pre-study Visit Checklist
	  	2	  	21 Feb 11
	 103.1 MED. 03 Pre-study Visit Report
	  	2	  	21 Feb 11
	 103.1 MED. 04 Follow-up Pre-study Visit Letter
	  	2	  	21 Feb 11
	 103.1 MED. 05 Site Selection Summary
	  	2	  	21 Feb 11
	 103.1 MED. 06 Site Selection letter
	  	2	  	21 Feb 11
	 103.1 MED. 07 Site Exclusion Letter
	  	2	  	21 Feb 11
	 103.1 MED. 08 Declaration on Facilities

103.1 MED. 09 Curriculum Vitae form

103.1 MED. 10 Contact Data Form

103.1 MED. 11 Pre-study Visit Agenda
	  	2
 3

2
 1
	  	21 Feb 11
 21 Jun 11

21 Feb 11
 21 Feb
11

			
	 104.1 MED. Informed Consent Form
	  	3	  	10 Nov 11
			
	 Associated Forms And Templates:
	  		  	
	 104.1 MED. 01 Informed Consent Form Approval Process
	  	2	  	10 Nov 11
	 104.1 MED. 02 Informed Consent Form Checklist
	  	2	  	10 Nov 11
	 104.1 MED. 03 Patient Information and Informed Consent Form Version Log
	  	2	  	10 Nov 11
	 104.1 MED. 04 Informed Consent Form local adjustment
	  	3	  	10 Nov 11

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

					
	 105.1 MED. Initiation Visit

 
 Associated Forms And Templates:

105.1 MED. 01 Confirmation Initiation Visit Letter

105.1 MED. 02 Site Initiation Visit Checklist

105.1 MED. 03 IMP Release Form

105.1 MED. 04 Site Green Light Approval

105.1 MED. 05 Site Initiation Visit Report

105.1 MED. 06 Delegation of Responsibilities Log

105.1 MED. 07 Site Visit Log

105.1 MED. 08 Subject Identification Log

105.1 MED. 09 Subject Screening and Randomization Log
	  	2  
 2

2
 2

2
 2

2
 2

3
 3
	  	04 Mar 11  

04 Mar 11
 04
Mar 11
 04 Mar 11

04 Mar 11
 04 Mar
11
 04 Mar 11
 04
Mar 11
 04 Mar 11

04 Mar 11

			
	 105.1 MED. 10 Follow-up Site Initiation Visit Letter

105.1 MED. 11 Financial Disclosure Form

105.1 MED. 12 Subject pre-screening Log

105.1 MED. 13 Site Initiation Visit Agenda
	  	2
 2

2
 2
	  	04 Mar 11
 04 Mar 11

04 Mar 11
 22 Jan
13

	 105.1 MED. 14 List of Site Initiation Visit Activities
	  	1	  	04 Mar 11
	 105.1 MED. 15 Consent to Processing Personal Data
	  	1	  	02 Jun 11
	 105.1 MED. 16 Instruction on How to Manage Consent for Personal Data in Clinical Operation Department
	  	1	  	27 Aug 12
			
	 106.1 MED. Monitoring Visit
	  	2	  	18 Apr 11
			
	 Associated Forms And Templates:
	  		  	
	 106.1 MED. 01 Confirmation Monitoring Visit Letter
	  	2	  	18 Apr 11
	 106.1 MED. 02 Monitoring Visit Report
	  	3	  	18 Apr 11
	 106.1 MED. 03 Contact Report
	  	2	  	18 Apr 11
	 106.1 MED. 04 Subject Visit Status
	  	2	  	18 Apr 11
	 106.1 MED. 05 Note to File
	  	3	  	18 Apr 11
	 106.1 MED. 06 Follow-up Monitoring Visit Letter
	  	2	  	18 Apr 11
	 106.1 MED. 07 Monitoring Visit and Reporting Plan
	  	2	  	18 Apr 11
	 106.1 MED. 08 Data Clarification Form

106.1 MED. 09 Site Personal Training Log

106.1 MED. 10 Confidentiality Violation Log
	  	1
 1

1
	  	18 Jul 11
 26 Jun 12

26 Jun 12

			
	 106.2 MED. Taking Over The Study
	  	3	  	31 May 13
			
	 Associated Forms And Templates:
	  		  	
	 106.2 MED. 01 CRA Site Take-Over Checklist
	  	5	  	31 May 13
	 106.2 MED. 02 CTA Take-Over Checklist
	  	2	  	31 May 13
			
	 106.3 MED. Co-Monitoring Visit
	  	2	  	25 Jul 11
			
	 106.3 MED. 02 Co-monitoring Visit Report: Quality Control Assessment
	  	2	  	25 Jul 11
			
	 106.4 MED. Reporting Protocol Deviations
	  	2	  	10Aug10
			
	 Associated Forms And Templates:
	  		  	
	 106.4 MED. 01 Protocol deviation report

106.4 MED. 02 Protocol Deviation Cumulative List
	  	2
 1
	  	10Aug10
 10Aug10

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

					
	 107.1 MED. Close-out Visit

 
 Associated Forms And Templates:

107.1 MED. 01 Confirmation Close-out Visit Letter

107.1 MED. 02 Close out Visits Plan

107.1 MED. 03 Close out Visit Checklist

107.1 MED. 04 Close out Visit Report

107.1 MED. 05 Record Retention Form

107.1 MED. 06 Site Close out Assessment

107.1 MED. 07 Follow-up Close out Visit Letter
	  	3	  	29 Dec 11
	  	2
 2

2
 2

2
 2

2
	  	30 Apr 11
 30 Apr 11

30 Apr 11
 30 Apr
11
 30 Apr 11
 30
Apr 11
 30 Apr 11

			
	 108.1 MED. Translation

Associated Forms And Templates:

108.1 MED. 01 Translation Certificate
	  	3  
 3
	  	19 Sep 11  
 19 Sep
11

			
	 109.1 MED. Clinial Trial Documents
	  	4	  	16 Sep 13
	 Associated Forms And Templates:
	  		  	
	 109.1 MED 01 Essential Documents
	  	4	  	16 Sep 13
			
	 109.3 MED. Trial Master File
	  	1	  	16 Sep 13
			
	 Associated Forms And Templates:
	  		  	
	 109.2 MED. 01 Trial Maser File Table of Content
	  	1	  	16 Sep 13
	 109.2 MED. 02 Trial Maser File and Shadow File Review Form

109.2 MED. 03 TMF Transfer Form

109 3 MED 04 Study Documentation Management Form
	  	1
 1

1
	  	16 Sep 13
 16 Sep 13

16 Sep 13

			
	 109.5 MED. Investigator’s File
	  	1	  	16 Sep 13
			
	 Associated Forms And Templates:
	  		  	
	 109.5 MED. 01 Investigator ́s File Table of Content
	  	1	  	16 Sep 13
			
	 109.5 MED. Electronic Study Folder and Shadow File

 
 109.7 MED.01 Shadow File Coordinators Log

109.7 MED.02 Electronic Folder Names

109.7 MED.03 Example of Electronic Study Folder and Shadow File Structure
	  	1  
 1

1
 1
	  	16 Sep 13  
 16 Sep
13
 16 Sep 13
 16
Sep 13

			
	 110.1 MED. Clinical Supplies
	  	3	  	16 Sep 13
			
	 Associated Forms And Templates:
	  		  	
	 110.1 MED. 01 Temperature Log
	  	3	  	16 Sep 13
	 110.1 MED. 02 Clinical Supply Shipment Management Log
	  	3	  	16 Sep 13
	 110.1 MED. 03 Clinical Supply Accountability Form
	  	3	  	16 Sep 13
	 110.1 MED. 04 Re-labelling Report
	  	3	  	16 Sep 13
	 110.1 MED. 05 Investigational product RECALL form
	  	3	  	16 Sep 13
	 110.1 MED. 06 Investigational product RETURN form
	  	3	  	16 Sep 13
	 110.1 MED. 07 Clinical Supply Destruction Report

110.1 MED.08 Site Investigational Product Accountability Log
	  	3
 1
	  	16 Sep 13
 16 Sep 13

			
	 111.1 MED. Clinical Trial Materials
	  	2	  	30 Sep 13
			
	 Associated Forms And Templates:
	  		  	
	 111.1 MED.01 Trial Supply Shipment Form
	  	4	  	30 Sep 13
	 111.1 MED.02 Controlled Copy Distribution Log
	  	3	  	30 Sep 13
	 111.1 MED.03 Frozen Samples storage log
	  	3	  	30 Sep 13
	 111.1 MED.04 Investigator’s Brochure Acknowledgement of Receipt
	  	2	  	30 Sep 13

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

					
	 112.1 MED. Serious Adverse Event Reporting
	  	3	  	08 Mar 13
			
	 Associated Forms And Templates:
	  		  	
	 112.1 MED. 01 SAE Pregnancy Report Form
	  	3	  	08 Mar 13
			
	 112.2 MED. Distribution of SUSAR reports
	  	2	  	15 Sep 11
			
	 Associated Forms And Templates:
	  		  	
	 112.2 MED. 01 SUSAR Reports Tracking Log
	  	2	  	15 Sep 11
			
	 112.5 MED. Safety Management Principles
	  	1	  	16 Sep 2013
			
	 114.1 MED. Insurance in Clinical Trial

 
 Associated Forms And Templates:

114.1 MED. 01 Questionnaire for Insurance Purposes
	  	3  
 3
	  	15 Apr 13  
 15 Apr
13

			
	 116.1 MED. Clinical Study Report
	  	3	  	28 Jun 13
			
	 Associated Forms And Templates:
	  		  	
			
	 116.1MED. 01 Clinical Study Report Tracking Log
	  	3	  	28 Jun 13
			
	 117.1 MED. Archiving Study Files
	  	3	  	09 Sep 13
			
	 Associated Forms And Templates:
	  		  	
	 117.1 MED. 01 Archiving Facility Log
	  	3	  	09 Sep 13
	 117.1 MED. 02 Archiving Coordinator Log
	  	2	  	09 Sep 13
	 117.1 MED. 03 Archiving Coordinator Backup Log
	  	2	  	09 Sep 13
	 117.1 MED. 04 Archiving Coordinator Take Over
	  	2	  	09 Sep 13
	 117.1 MED. 05 Post Study Checklist
	  	3	  	09 Sep 13
	 117.1 MED. 06 Content of Archived Box
	  	2	  	09 Sep 13
	 117.1 MED. 07 List of Archived Studies
	  	2	  	09 Sep 13
	 117.1 MED. 08 Retrieve from Archives Request
	  	2	  	09 Sep 13
	 117.1 MED. 09 Confirmation of Destruction
	  	2	  	09 Sep 13
	 117.1 MED. 10 Inventory of Archiving Boxes
	  	2	  	09 Sep 13
	 117.1 MED. 11 Inventory of Archiving Locking Seals
	  	2	  	09 Sep 13
	 117.1 MED. 12 Content of Archiving File
	  	2	  	09 Sep 13
			
	 117.3 MED Management of Electronic Correspondence
	  	1	  	29 Mar 13
			
	 121.1 MED. Contracts with Investigators and Investigational Sites
	  	4	  	01 Feb 10
			
	 Associated Forms And Templates:

121.1 MED. 01 Bilateral contract (investigator)

121.1 MED. 02 Bilateral contract (centre)
	  	4
 4
	  	08 Aug 11
 08 Aug 11

	 121.1 MED. 03 Tripartite contract (investigator & centre)

121.1 MED. 04 Bilateral contract (investigator-coordinator)

121.1 MED. 06 Lend agreement (investigator)

121.1 MED. 07 Lend agreement (centre)

121.1 MED. 08 Service agreement (contractor with team)
	  	4
 4

2
 2

2
	  	08 Aug 11
 08 Aug 11

08 Aug 11
 08 Aug
11
 08 Aug 11

			
	 121.1 MED. 09 Service agreement (single contractor)

121.1 MED. 10 Bilateral contract (investigator) – MD

121.1 MED. 11 Bilateral contract (centre) – MD
	  	2
 2

2
	  	08 Aug 11
 08 Aug 11

08 Aug 11

	 121.1 MED. 12 Tripartite contract (investigator & centre) – MD
	  	2	  	08 Aug 11

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

					
	 121.1 MED. 13 Bilateral contract (investigator-coordinator) – MD
	  	2	  	08 Aug 11
			
	 122.1 MED. Confidentiality Agreements and Confidentiality Obligation
	  	3	  	14 Mar 11
			
	 Associated Forms And Templates:

122.1 MED. 01 CA general unilateral (investigator - centre)

122.1 MED. 02 CA study specific unilateral (investigator - centre)

122.1 MED. 03 CA general unilateral (sponsor - contractor - other)

122.1 MED. 04 CA study specific unilateral (sponsor - contractor - other)

122.1 MED. 05 CA general mutual (sponsor - contractor - other)

122.1 MED. 06 CO in feasibility only (investigator)

122.1 MED. 07 CA/CO explanatory notice
	  	2
 2

2
 2

2
 3

2
	  	15 Feb 11
 15 Feb 11

15 Feb 11
 15 Feb
11
 15 Feb 11
 15
Feb 11
 01 Mar 11

			
	 123.1 MED. Principles of drawing contracts and master service agreements
	  	2	  	28 Mar 11
			
	 Associated Forms And Templates:
	  		  	
	 123.1 MED. 01 KCR Group Contract Template:

        Master Service Agreement

123.1 MED. 02 KCR Group Contract Template:

        Service Agreement for a clinical study conduct
	  	2  
 1
	  	28 Mar 11  
 20
Oct 08

			
	 124.1 MED. Fraud and Misconduct
	  	3	  	11 Feb 13
			
	 125.1 MED. Purchases Within a Project
	  	1	  	25 Jul 11
			
	 127.1 MED. Legislation in Clinical Trials
	  	2	  	31 Jul 13
			
	 127.3 MED Regulatory Intelligence

 
 Associated Forms And Templates:

127.3 MED.01 Regulatory Intelligence Responsibilities
	  	1  
 1
	  	28 Dec 12  
 28
Dec 12

			
	 128.1 MED. Communication with Subcontractor

 
 Associated Forms And Templates:

128.1 MED. 01 Subcontractor Tracking Log
	  	1  
 1
	  	01 Sep 11  
 01
Sep 11

			
	 129.1 MED. Annual Progress Report to Competent Authorities 
	  	2	  	30 Sep 11
			
	 Associated Forms And Templates:
	  		  	
	 129.1 MED. 01 Annual Progress Report Template
	  	2	  	30 Sep 11
			
	 130.1 MED. Preparing Monitoring Plan
	  	1	  	25 Nov 11
			
	 Associated Forms And Templates:
	  		  	
	 130.1 MED. 01 Monitoring Plan
	  	1	  	25 Nov 11
			
	 131.1 MED. Communication Plan

 
 Associated Forms And Templates:

 
	  	1	  	30 Apr 12
	 131.1 MED. 01 Communication GLOBAL Contact List
	  	1	  	30 Apr 12
	 131.1 MED. 02 Communication COUNTRY Contact List
	  	1	  	30 Apr 12
	 131.1 MED. 03 Communication VENDOR Contact List
	  	1	  	30 Apr 12
	 131.1 MED. 04 Study Team Delegation Log
	  	1	  	30 Apr 12
	 131.1 MED 05 Communication Plan
	  	1	  	30 Apr 12

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

					
	 132.1 MED. Unbliding
	  	1	  	28 Aug 12
			
	 Associated Forms And Templates:

132.1 MED. 01 Unblinding Contact List

132.1 MED. 02 Unblinding Report

132.2 MED. 03 Unblinding Listing
	  	1
 1

1
	  	28 Aug 12
 28 Aug 12

28 Aug 12

			
	 134.1.MED Principal Investigator Change

Associated Forms And Templates:

134 1 MED 01 Principal Investigator Change Checklist 131.1.MED.03

134 1 MED 02 Letter to Competent Authorities About Principal Investigator Change
	  	1  
 1

1
	  	04 Apr 13  
 04 Apr
13
 04 Apr 13

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 Attachment No. 5 

List of third parties engaged by the Sponsor for the conduct of the Study 

 

	 	a.	Legal representative (SCIderm GmbH): CRO shall undertake the following obligation, and shall indemnify the sponsor for any damage in case it will breach such obligation: notify immediately SCIderm GmbH and the Sponsor
of any untoward occurrences, including serious breaches of the protocol, GCP or regulations, occurring in the clinical trial. 

  

	 	b.	Data Management: CRO shall act according to the procedures, as shall be determined for this clinical trial. 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 [***] 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 [***] 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 [***] 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 [***] 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 [***] 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 

 
  

 [***] 

  

			
	 VBL
 Confidential Information

	  	 Page 1 of 64 Version

2.2 02 DEC 2013

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].EX-10.14

 Exhibit 10.14 

Unprotected lease Agreement 

Drawn up and signed in Or-Yehuda on the             day of the month of January 2013 

 

			
	Between:	  	 Maslavi Construction Co. Ltd.
 1 Aviv
Moshe St., Or-Yehuda Industrial Zone
 Tel.: 03-5339212 ; Fax: 03-5338437

(hereinafter: “Landlord”)
  

Of the first part

		
	And between:	  	 Vascular Biogenics Ltd Company No. 512899766

Of 6 Yonni Netanyahu St.
 Or-Yehuda

(hereinafter: “Tenant”)
  

Of the second part

  

			
	Whereas:	  	The Landlord is the registered lessee of the Leased Premises within their meaning hereunder;
		
	And whereas:	  	The Tenant wishes to lease the property from the Landlord in unprotected lease for the period and under the terms as specified in this Agreement hereunder and the Landlord agreed to lease the said property to the Tenant, in
accordance with the provisions set forth in this Agreement;

 Therefore, it is Declared, Stipulated and Agreed between the Parties as Follows: 

 

	1.	Introduction 

  

	 	1.1.	The preamble to this Agreement shall be deemed an integral part hereof. 

  

	 	1.2.	The headings of the clauses will serve for the purpose of orientation and convenience only, and will not serve for the purpose of interpreting the Agreement. 

 

	2.	Definitions 

  

	 	2.1.	“Leased Premises” – a built area situated in a building known as the “Aviv 2000” building in 6 Yonni Netanyahu St. in the town of Or-Yehuda (hereinafter: “Building”) in gross area of
825sqm situated on the first and ground floor of the building and 20 parking spaces. 

  

	 	2.2.	“Term of Lease” – a period taking effect on 1.10.12 and expiring on 30.9.2013; 

  
 1 

	 	2.3.	“Option Term” – two periods of 12 months each; 

  

	 	2.4.	“Basic Index” – the consumer price index known on the date of signing this Agreement; 

  

	 	2.5.	“Known Index” – the consumer price index known on the date of making any payment, and in any event shall not fall below the Basic Index; 

 

	 	2.6.	“Monthly Rent” – the basic rent paid by the Tenant during the Term of Lease for each month of lease and that shall be in the amount of NIS 43,697 + VAT, index-linked as specified hereunder;

  

	 	2.7.	“Management Fees”: the management fees paid by the Tenant during the Term of Lease for each month of lease, and that shall be in the amount of NIS 9,075 + VAT index-linked as specified hereunder;

  

	 	2.8.	“Additional Parking Payment” – a monthly payment in the amount of NIS 6,127 + VAT in respect of 20 parking spaces; 

  

	 	2.9.	“Purpose of Lease” – biotechnology industries, laboratories for chemical and microbiological testing; 

  

	 	2.10.	“Term of Payment” – each month; 

  

	 	2.11.	“Bank Guarantee” – an autonomous bank guarantee in an amount equal to the monthly rent X 4, index-linked and in effect as of the lease commencement date and up to 3 months following expiration of the Term
of Lease. 

  

	3.	Term of Lease 

  

	 	3.1.	The Landlord hereby leases to the Tenant and the Tenant hereby leases from the Landlord the Leased Premises for the Term of Lease within its meaning hereinabove. In addition, the Tenant is granted the option to extend
the Term of Lease for the option terms within their definition hereinabove (hereinafter: “Option Terms”) on the condition that the Tenant upheld the terms of lease during the previous Term and/or terms of lease fully and to the
satisfaction of the Landlord. 

  

	 	3.2.	In the event the Tenant failed to deliver written notice to the Landlord regarding its wish to terminate the lease under this Agreement no later than three (3) months prior to expiration of the Term of Lease, this
shall be deemed as if the Tenant delivered the Landlord a notice on extension of the Term of Lease by the additional term of lease and the lease shall be extended automatically under the terms set forth in this Agreement for additional unprotected
terms of lease. 

  

	 	3.3.	The terms of lease in the additional term of lease shall be identical to the terms of lease in the first Term of Lease, subject to modifications that were set forth expressly in the Agreement and except for rent that
shall vary as specified hereunder. 

  
 2 

	 	3.4.	Notwithstanding anything said or implied to the contrary in this Agreement, the parties agree that this Agreement shall be terminated upon delivery of a notice to the Tenant effective immediately, immediately upon the
occurrence of one of the following events: a bankruptcy order was delivered against the Tenant and/or a receivership order was issued against any of the controlling shareholders in the Tenant and/or the Tenant made an arrangement with and/or in
favor of his creditors and/or a receiver or a trustee or any other officer that is identical or similar in essence to any of the positions of the said officers was appointed, or a motion for bankruptcy of the Tenant was filed and the motion was not
stricken within 30 days. The Tenant shall be granted a 30 days’ extension to strike any of the orders enumerated in this clause. To dispel any doubt it is clarified that termination of the Agreement under the circumstances specified hereinabove
shall constitute a fundamental breach of the Agreement on behalf of the Tenant. 

  

	4.	Purpose of Lease 

  

	 	4.1.	The Tenant shall use the Leased Premises solely for the Purpose of Lease as specified hereinabove, or for any other legal purpose agreed by the Landlord and not for any other purpose. 

 

	 	4.2.	The Tenant shall be responsible to obtain all the certificates and/or licenses that are required for the purpose of using the property for the Purpose of Lease. Failure to obtain a permit or a license shall not serve as
cause to terminate this Agreement by the Tenant or as cause to terminate the lease subject matter of this Agreement or by virtue of this Agreement. The Landlord shall sign, at the Tenant’s request, any document that is required by the
authorities and that requires the signature of the owners/leaseholders and this shall not impose on the Landlord any financial liability and provided that the said request complies with the provisions set forth in this Agreement and any relevant
law. The foregoing shall not apply to payments that apply by law or practice to the owner and/or holder of lease rights in the property. 

  

	 	4.3.	The Landlord shall not be obligated to make any payment in connection with obtaining the certificates and licenses as said. In the event the Landlord was charged with such payment as said, the Tenant shall indemnify the
Landlord in respect of any amount it is charged as specified hereinabove. 

  

	 	4.4.	 The Tenant affirms that it inspected the Leased Premises and found them suitable for its requirements and it hereby waives any allegations regarding
lack of conformity or any other claims. At the time of signing this Agreement the Landlord undertakes to take measures to remove the 

  
 3 

	 	
humidity under the floor in the ground floor within 90 days and inquire the odor nuisance in the first floor as argued by the Tenant and make repairs if necessary. 

 

	 	4.5.	Inspection by the Landlord 

  

	 	4.6.	The Landlord and/or representative thereof shall be entitled to visit the Leased Premises at any time during regular business hours and following advance coordination in order to examine and see whether the terms set
forth in this Agreement are fully observed. 

  

	5.	Rent 

  

	 	5.1.	Monthly rent that the Tenant shall pay to the Landlord during the first Term of Lease within its meaning hereinabove shall be the monthly rent as specified hereinabove. Statutory VAT shall be added to the said rent.

  

	 	5.2.	In addition to the Rent, the Tenant shall make additional payment for the parking spaces, within their meaning hereinabove. The additional Parking Payment shall be paid together with the monthly rent and all terms set
forth with regard to the monthly rent shall also apply to the additional Parking Payment. 

  

	 	5.3.	At the time of signing this Agreement the Tenant shall furnish to the Landlord postdated checks for the entire Term of Lease in a manner that 7 days before commencement of each term of payment, within its meaning
hereinabove, a check shall be repaid for each term of payment. The first check shall be a cash check as of the date of signing this Agreement. Two months prior to commencement of each Option Term, and to the extent that no notice was delivered
regarding termination of lease, the Tenant shall furnish to the Landlord new checks in respect of the additional term, in accordance with the provisions set forth hereinabove, otherwise its right to exercise the option shall expire.

  

	 	5.4.	Rent shall be paid in new Israeli shekels and shall be linked to the index in a manner that upon expiration of the Term of Lease and upon expiration of each Option Term the Tenant shall pay to the Landlord the
difference between linkage of each payment to the Basic Index and the Known Index, within their meaning hereinabove. In any event of delay in payment, for any reason that is contingent on the Tenant, the Tenant shall make payment according to the
index known on the payment date applicable in accordance with this Agreement, or on the date of payment – upon the higher. 

  

	 	5.5.	In the event the Tenant vacated the Leased Premises for any reason prior to expiration of the first Term of Lease, or in the middle of an Option Term, the Tenant shall be obligated to pay rent for the entire Term of
Lease and/or Option Term. 

  
 4 

	 	5.6.	Without derogating from for any relief and/or remedy that Landlord may seek in accordance with the provisions set forth in this Agreement and/or in accordance with the provisions set forth in any law then any default in
payment of any amount shall incur 1.5% interest per month. 

  

	 	5.7.	A one-time default in payment for a period of up to 7 days shall not grant interest to the Landlord as said. Default in payment for a period that is longer than 7 days shall entitle the Landlord with interest in arrears
as of the first day of default and until payment is made. 

  

	 	5.8.	A default in payment for a period of 14 days shall constitute a fundamental breach of this Agreement, and in such circumstances the Landlord shall not be obligated to deliver to the Tenant any additional notice prior to
termination of the Agreement. 

  

	 	5.9.	The said in this sub-clause shall not derogate or affect the provisions set forth in clause 16 hereunder. Interest shall be deemed as rent. 

 

	 	5.10.	To dispel any doubt, furnishing the checks shall not be deemed as payment however only 3 days after their cashing on the dates designated for that purpose. Rent shall be paid in the address of the Landlord or shall be
deposited in the Landlord’s bank account in accordance with the instructions set forth by the Landlord. 

  

	6.	Management Fees 

  

	 	6.1.	In addition to the monthly rent the Tenant undertakes to pay the Landlord, during the entire Term of Lease and/or the Option Term, Management Fees within their meaning hereinabove. Statutory VAT shall be added to the
Management Fees. The Landlord shall be entitled, at its sole discretion, to provide current management and maintenance services for the Tenant and all other tenants/users of the Building whether by itself or by others acting on its behalf.
Management and maintenance services that are provided by the Landlord or anyone acting on its behalf shall include, inter alia, cleaning and lighting of public areas; air conditioning in any thereof and at the discretion of the Management
Company; gardening of the gardens and vegetation in the public areas, maintenance, repair and preservation of the public areas, and maintenance and repair of equipment (except for spare parts and the equipment itself or parts thereof, to the extent
required) that are in service of the project and/or all tenants in the Building or majority thereof and that is not owned and/or under the responsibility of any tenant, such as generators, gas and fuel tanks, sewage systems, plumbing, electricity,
drainage, lighting, elevators and escalators in the public areas, whitewashing and painting the public areas; sealing and repair of the roofs of the Building; security and protection of the Building. 

  
 5 

	 	6.2.	Management Fees shall be paid jointly with the monthly rent and all terms set forth with respect to the monthly rent shall also apply to the Management Fees. 

 

	 	6.3.	The Tenant is aware that due to the special nature of the Building and the diverse uses made therein different instructions and restrictions shall be set forth and shall apply to all units and possessors therein in the
agreement with the Management Company and the instructions set forth by the Management Company as set forth from time to time. These restrictions will include, inter alia, and without derogating from the generality of the aforesaid,
restrictions on the use of electricity and water according to permitted loads, transportation, loading and unloading procedures, use of elevators, signage, advertising, services and cleaning. The Tenant undertakes to uphold all the instructions set
forth hereinabove on the condition that they do not affect the Tenant’s rights in accordance with this Agreement, and the Tenant shall be held liable for any damage and/or loss and/or expense caused to the Landlord and/or any other entity as a
result of breach of this undertaking. Without derogating from the generality of the aforesaid, in any event the Tenant wishes to increase the electricity capacity that is allocated and in the event that the increase is made possible, it shall be
implemented on the condition that the Tenant upholds all the instructions and requirements set forth by the Landlord and/or the Management Company, including the payment of any additional expenses or amounts required in respect of the change.

  

	7.	Taxes, Charges and Obligatory Payments 

  

	 	7.1.	The Tenant shall incur all taxes, charges, payments and municipal and/or other payments applicable to the property and/or relating to the property and/or the lease subject matter of this Agreement and that exist at
present and/or that will be imposed in the future (except for government property tax and new taxes of similar nature that will be imposed on the owner of the property as opposed to a possessor or user or tenant etc. per se), and the Tenant shall
pay the said payments regularly and timely. The Tenant shall further pay regularly and timely all other expenses including electricity, water, telephone, tenants committee etc. For the purpose of securing the said payments the Tenant shall deliver a
copy of the Agreement to the different authorities (municipality and the electricity company), and shall be registered as the payer in the bills. In the event the Tenant failed to act in the said manner the Landlord shall be entitled, without
derogating from the undertaking of the Tenant, to act in the said manner, to deliver a copy of this Agreement to any of the authorities and/or institutions in favor of which the said payments are made and to inform them about the existence of this
Agreement, in a manner that the payer of the said bills shall be the Tenant. 

  
 6 

	 	7.2.	In the event that the Leased Premises have one electricity meter, together with another unit and/or units in the Building, then the Tenant shall pay the electricity bill jointly and severally with the other tenant(s)
who are connected to the said meter. The Tenant shall pay the bills in proportion to the area of the Leased Premises, unless otherwise agreed between the parties. 

 

	 	7.3.	The Tenant shall furnish certificates and receipts attesting that the payments that the Tenant is obligated to pay in accordance with this Agreement were duly made, at the Landlord’s request. The Landlord shall be
entitled (however not obligated) to pay any amount applicable to the Tenant in accordance with this Agreement and that was not paid by the Tenant within 10 days as of the date set forth for its payment or as of the date that payment was supposed or
is supposed to be paid, provided that it delivered the Tenant a 7 days prior notice in respect whereof. The Tenant shall return to the Landlord any amount paid as said, in addition to a fine at a 25% rate at least, together with linkage
differentials and interest as specified hereinabove, as of the date that the said amount was paid by the Landlord and until the said payment is returned to the Landlord by the Tenant. The amounts due to the Landlord from the Tenant in accordance
with the provisions set forth hereinabove shall be deemed as rent. The provisions set forth in this clause shall not affect and/or derogate from the right of the Tenant to seek any relief or remedy it may seek in accordance with the provisions set
forth in this Agreement and/or in accordance with the provisions set forth in any law. 

  

	 	7.4.	Statutory VAT shall be paid by the Tenant together with and in addition to payment of rent. The Landlord shall furnish licensed dealer invoices to the Tenant. 

 

	8.	Use of the Leased Premises 

  

	 	8.1.	The Tenant undertakes to use the Leased Premises in a reasonable and cautious manner and to see that during the entire term of use the Leased Premises and all facilities and installations thereof are in kept in working
order. 

  

	 	8.2.	Without derogating from the foregoing, the Tenant undertakes to repair within a reasonable time and at its expense any defect and/or malfunction that it caused in the Leased Premises, and/or any other facility in
connection with the Leased Premises in any manner (provided that the defects do not require immediate repair, and then the Tenant undertakes to repair the defect and/or the malfunction it caused in the Leased Premises forthwith) except for defects
or malfunctions deriving from reasonable wear (which the Landlord is responsible to repair). 

  
 7 

	 	8.3.	The Landlord undertakes to repair any defect or malfunction that was caused to the Leased Premises and that derives from reasonable wear and ordinary use within a reasonable time, subject to receiving a written notice
from the Tenant regarding the malfunction that was caused in the Leased Premises (provided that the said defects do not bar reasonable use of the Leased Premises, and in such circumstances the Landlord undertakes to repair the defect and/or the
malfunction forthwith). The Tenant undertakes to notify the Landlord forthwith upon becoming aware of any defect or malfunction as said. Any damage caused as a result of failure by the Tenant to deliver notice to the Landlord as specified in this
clause shall be solely incurred by the Tenant. 

  

	 	8.4.	The liability of the Landlord under this Chapter shall not apply where the Tenant caused a defect and/or damage by its act and/or omission and/or an act and/or omission committed by anyone acting on its behalf, and in
the event the defect or the breakdown malfunction from faulty maintenance on behalf of the Tenant and/or anyone acting on its behalf and/or due to misuse and/or negligent use and/or by an act and/or omission of the Tenant and/or due to works and/or
alterations that were implemented not by the Landlord and/or materials and/or products that were purchased directly by the Tenant and/or due to failure to observe instructions or warnings, to the extent provided by the Landlord, regarding special
features of the Leased Premises and/or the common property, by the Tenant. 

  

	 	8.5.	In the event one of the parties failed to repair a defect and/or malfunction it was obligated to repair as said, the other party shall be entitled (however not obligated) to make the said repair at the expense of the
other party and provided that it delivered a written notice to the other party regarding its intention to act in the said manner and the other party failed to make the repairs within 30 days as of the date of receiving notice, without derogating or
affecting its rights to seek any relief or remedy in accordance with the provisions set forth in this Agreement and/or in accordance with the provisions set forth in any law. The foregoing with regard to return of amounts that were expended by the
party that made the repair in addition to interest as specified hereinabove shall apply, mutatis mutandis as the case may be, also for the purpose of amounts that are expended by one of the parties in accordance with the provisions set forth
in this sub-clause. 

  
 8 

	9.	Prohibition on Implementation of Alterations 

  

	 	9.1.	The Tenant is prohibited from implementing and/or adding any alteration and/or adding any construction addition in the Building wherein the Leased Premises are located without obtaining the prior and written consent of
the Landlord. In the event the Tenant acted or attempted to act in contravention of the said, the Landlord shall be entitled to deny from the Tenant implementation of any alteration and/or any construction addition as specified hereinabove, and to
demand their immediate disposal and/or dispose them by itself, and the Tenant shall be obligated to pay to the Landlord, immediately upon its first request, all expenses in connection with the disposal and demolition as said that shall constitute a
debt of the Tenant to the Landlord in accordance with this Agreement. 

  

	 	9.2.	Any amounts that are due to the Landlord in accordance with the provisions set forth in this clause shall incur interest at the rate set forth in clause 7.6 hereinabove as of the date the payment was made by the
Landlord and until these amounts are paid to the Landlord. 

  

	 	9.3.	The Tenant shall not be entitled to install any signs without obtaining the prior and written consent of the Landlord. In addition, and in the event the Landlord allows the Tenant to install signage, then any tax and/or
expense incurred in connection with the installation of signage shall be incurred by the Tenant. 

  

	10.	Assignment of Rights 

  

	 	10.1.	The Landlord shall be entitled to transfer its rights (or a part thereof) in the Leased Premises to another/others without obtaining the consent of the Tenant in connection therewith, provided that the Tenant’s
rights in accordance with this Agreement shall not be affected as a result of and/or following the transfer of rights as said. 

  

	 	10.2.	The Tenant shall not be entitled to assign and/or transfer and/or convey his rights in accordance with this Agreement without obtaining the prior and written consent of the Landlord. For the sake of caution, and without
derogating from the generality of the aforesaid, it is clarified that the Landlord shall be entitled to withhold consent to assignment of rights at its sole discretion. Any transfer and/or assignment of rights without obtaining the consent of the
Landlord shall be null and void and the Landlord shall be entitled to terminate this Agreement forthwith, and this shall not be deemed as a fundamental breach of this Agreement by the Tenant. 

 

	 	10.3.	It is agreed that Section 22 of the Hire and Loan Law 5731-1971 shall not apply to this Agreement. 

  
 9 

	11.	Vacating the Leased Premises 

  

	 	11.1.	Upon expiration of the Term of Lease or in any other time in which the Tenant is obligated to vacate the Leased Premises or in which the Tenant vacates the Leased Premises, the Tenant shall return to the Landlord
possession in the Leased Premises when the Leased Premises are vacated from any person and article and in the condition the Tenant received the Leased Premises (when all its fixtures and installations are in working order). 

 

	 	11.2.	The Tenant undertakes to whitewash the walls and clean the Leased Premises thoroughly upon expiration of the Term of Lease. 

  

	12.	Non-Applicability of Tenancy Protection Laws 

  

	 	12.1.	The Tenant declares that he did not pay and will not pay key money to the Landlord and that the provisions set forth in the Tenant Protection Law [Consolidated Version] 5732-1972 will not apply to the Leased Premises
and/or the lease subject matter of this Agreement or any other provisions added to or that come in lieu of the provisions set forth in the said law. 

  

	 	12.2.	The lease subject matter of this Agreement is unprotected lease in accordance with the Tenant Protection Law and the Tenant undertakes to refrain from arguing otherwise. It is agreed that any allegation made by the
Tenant that does not comply with the foregoing shall not be heard. 

  

	13.	Securities 

  

	 	13.1.	For the purpose of securing the full and accurate performance of each of the Tenant’s undertakings in accordance with this Agreement, the Tenant shall furnish a bank guarantee within its meaning hereinabove.

  

	 	13.2.	7 days prior to realizing the guarantee by the Landlord the Landlord shall notify the Tenant about its intention to realize the guarantee and will allow the Tenant to remedy the breach. 

 

	 	13.3.	The Landlord shall be entitled to use the bank guarantee for the purpose of collecting all payments, debts, taxes and charges due to the Landlord and/or that apply to the Tenant in accordance with the provisions set
forth in this Agreement (including for the purpose of making payment to third parties) and for the collection of damages in respect of damage caused to the Leased Premises during the Term of Lease and/or for the purpose of covering for expenses,
provided that the Tenant receives a notice 7 business days in advance to make the said payments. 

  

	14.	Prerequisites for Delivery of Possession in the Leased Premises – Canceled 

  

	15.	Breaches 

  

	 	15.1.	 Failure to make payment of Rent accurately and timely as specified in this Agreement and/or default in making any payment applicable to the Tenant
(such as municipal taxes, electricity etc.) and/or using the Leased Premises 

  
 10 

	 	
in contravention of the Purpose of Lease and/or failure to accept and/or extend any security, including and in particular the bank guarantee and/or failure to vacate the Leased Premises on the
dates specified in this Agreement (including and in particular upon expiration of the Term of Lease) and/or implementation of alterations in the Leased Premises without obtaining the Landlord’s consent and/or assignment of rights without
obtaining the Landlord’s prior and written consent shall be deemed as a fundamental breach of this Agreement with all ensuing consequences, and shall entitle the Landlord to demand eviction of the Tenant from the Leased Premises in addition to
any other relief or remedy that the Landlord may seek in accordance with the provisions set forth in this Agreement and/or in accordance with the provisions set forth in any law. In such circumstances, the Landlord shall deliver to the Tenant a 14
days’ prior notice notifying the Tenant about the breach and a period of time for remedying the breach during the said period. In the event the Tenant fails to remedy the breach during the said period of time the Landlord shall be entitled to
demand from the Tenant to vacate the Leased Premises and in such circumstances the Tenant shall vacate the Leased Premises within 72 hours as of the time of receiving notice to that effect, in accordance with the provisions set forth clause 13
hereinabove, and the Landlord shall be entitled to realize the securities. 

  

	 	15.2.	In addition, and without derogating from the provisions set forth in sub-clause (a) hereinabove, the Tenant shall pay the Landlord an amount equal to 250% of the monthly rent as liquidated damages and without proof
of damage, for each month of delay (and for part of a month – part of the liquidated damages) in respect of each day of delay in making payment and/or vacating the Leased Premises, whether upon expiration of the Term of Lease and whether in any
other time in which the Tenant is obligated to vacate the Leased Premises in accordance with the provisions set forth in this Agreement or in circumstances arising out of this Agreement, and after delivering a 14 days’ notice from the Landlord
following which the breach was not remedied, in addition to the rent and the current payments applicable to the Leased Premises (such as municipal taxes, electricity etc.). The liquidated damages shall be paid to the Landlord within 7 days as of the
date the Tenant is required to make that payment by the Landlord. Notwithstanding the said it is agreed that a delay in vacating the Leased Premises of up to 7 days and a onetime default in payment of the rent shall not entitle the Landlord with any
compensation, except for rent in proportion to the period of delay, however a default in payment longer than 7 days or a repeated default in payment shall entitle the Landlord with the liquidated damages as specified hereinabove as of the first date
of the default. 

  
 11 

	 	15.3.	For the sake of caution it is clarified that the compensation specified hereinabove shall be in addition to any relief that the Landlord may seek in accordance with the provisions set forth in this Agreement and/or in
accordance with the provisions set forth in any law. 

  

	 	15.4.	To dispel any doubt, a default in payment in the four first months of the lease deriving from a delay in signing this Agreement shall not be deemed as default in accordance with this clause. 

 

	16.	Seizing Possession by the Landlord 

  

	 	16.1.	In addition to any other relief or remedy that the Landlord may seek in accordance with the provisions set forth in this Agreement and/or in accordance with the provisions set forth in any law, the Landlord shall be
entitled, in the event of failure to vacate the Leased Premises by the Tenant upon expiration of the Term of Lease, and in circumstances of default in any payment of rent and/or obligatory payments imposed on the Tenant, and in any other
circumstances in which the Tenant is obligated to vacate the Leased Premises, to enter and seize possession of the Leased Premises in any manner it deems fit and take all measures for the purpose of evicting the Tenant from the Leased Premises and
shall be entitled to store, in any location it deems fit and at the Tenant’s expense, any of the Tenant’s possessions that are located in the Leased Premises or dispose the said possessions from the Leased Premises and leave them anywhere
the Landlord deems fit. In addition, the Landlord shall be entitled to restore the Leased Premises to their condition as specified in clause 13 hereinabove and charge the Tenant with payment of expenses that the Landlord incurred in connection
therewith. 

  

	 	16.2.	The Landlord shall not be held liable for any damage caused as a result of or following such action as said for any reason. After the date set forth or that will be set forth for vacating the Leased Premises (whether
upon expiration of the Term of Lease or on any other date, including due to termination of the Agreement due to its breach by the Tenant) the Tenant shall be deemed as trespasser in the Leased Premises for all intents and purposes.

  

	 	16.3.	The Tenant shall pay to the Landlord amounts expended by the Landlord as a result of actions of evacuation performed by the Landlord or anyone acting on its behalf and the Tenant grants its consent to the activities of
the Landlord or anyone acting on its behalf in the circumstances in question within 7 days as of the date it is required by the Landlord to make the said payment. The amounts that were paid in default shall incur linkage differentials according to
the linkage mechanism set forth for the rent. 

  
 12 

	17.	Liability 

  

	 	17.1.	Without derogating from the provisions set forth in the principal agreement and in addition to the provisions set forth thereat, it is agreed that the Tenant shall incur any liability imposed on it by law for any loss,
damage or damage or loss to the body and/or property of any kind caused to the Tenant and anyone acting on its behalf and/or to the Landlord and anyone acting on its behalf and/or to any third party including, however without derogating from the
generality of the aforesaid, the employees and/or suppliers and/or visitors and/or workers of the Landlord and/or anyone acting on its behalf due to an act and/or omission of the Tenant and/or anyone acting on its behalf in anything related to the
Leased Premises provided that the damage was not caused by the Landlord negligently and/or willfully. 

  

	 	17.2.	The Tenant undertakes to indemnify the Landlord for the full amounts the Landlord was instructed to pay in a judgment whose performance was not stayed following a claim for loss or damage for which the Tenant is liable
as specified in clause 18.1 hereinabove, and for reasonable costs that the Landlord incurred for the purpose of defending against the said claim. The Landlord shall notify the Tenant within a reasonable time about receiving any demand and/or claim
in respect of the said in clause 18.1 and shall allow the Tenant or its authorized representative to defend against it. 

  

	18.	Insurance 

  

	 	18.1.	In the event any works are implemented in the Leased Premises not by the Landlord however by the Tenant and/or anyone acting on his behalf at any time during the Term of Lease, the Tenant undertakes to furnish to the
Landlord the Insurance Certificate for the Tenant’s works enclosed with this Addendum and constituting an inseparable part thereof, marked as Appendix 1 (hereinafter respectively: “Tenant’s Works Insurance Certificate” and
“Tenant’s Works Insurance”) signed by its insurer. The Tenant declares that it is aware that furnishing the Tenant’s Works Insurance Certificate as said is a suspending condition and a prerequisite for implementing any works in
the Leased Premises, and the Landlord shall be entitled (however not obligated) to deny from the Tenant implementation of the works in the Leased Premises, in the event the said Certificate was not furnished to it prior to commencement of the works.

  

	 	18.2.	 Notwithstanding the said in clause 19.1 hereinabove, in the event the amount of the works implemented as specified hereinabove is not greater than NIS
200,000 then the Tenant shall be entitled, instead of arranging 

  
 13 

	 	
the Tenant’s Works Insurance, to furnish to the Landlord an Insurance Certificate as specified in Appendix 2 (Tenant’s Insurance Certificate) hereunder, provided that the following
shall be added in the final part of the Certificate: “To dispel any doubt it is clarified that the insurance specified hereinabove shall also apply at the time of implementing any works during the insurance period by the Tenant and/or anyone
acting on its behalf, including construction, adjustment, betterment, renovation, dismantling works etc.” 

  

	 	18.3.	Without derogating from the liability of the Tenant in accordance with the provisions set forth in this Agreement and/or in accordance with the provisions set forth in any law, the Tenant undertakes, without receiving
any notice from the Landlord, to furnish to the Landlord Appendix 2 hereunder “Tenant’s Insurance Certificate,” signed by its insurer, no later than the date of receiving possession of the Leased Premises or before the date of
bringing any assets to the Leased Premises (except for assets that are included in the works insured under clause 19.1 hereinabove) – upon the earlier. The Tenant declares that it is aware that furnishing the Tenant’s Insurance Certificate
is a suspending condition and a prerequisite for receiving possession in the Leased Premises and/or bringing any assets into the Leased Premises and/or the area (except for assets that are included in the worked insured under clause 19.1
hereinabove) and the Landlord shall be entitled (however not obligated) to deny from the Tenant receiving possession in the Leased Premises and/or bringing assets as said in the event that the Certificate was not furnished prior to the date
specified hereinabove. 

  

	 	18.4.	It is agreed that the Tenant may not arrange consequential loss insurance, in whole or in part, as specified in clause (4) of Appendix 2 of the Tenant’s Insurance Certificate, however the exemption specified
in clause 19.8 hereunder shall apply as if the said insurance was fully arranged. 

  

	 	18.5.	It is agreed that the Tenant shall be entitled not to arrange insurance coverage for glass breakdown, in whole or in part, as specified in clause (1) of the Tenant’s Insurance Certificate, however the
exemption specified in clause 19.8 hereunder shall apply as if the said insurance was fully arranged. 

  

	 	18.6.	If the Tenant is of the opinion that an additional and/or supplemental insurance is required in addition to the insurance of the Tenant’s works and/or the Tenant’s insurances, the Tenant undertakes to arrange
and maintain the additional and/or supplemental insurance as said. In any additional or supplemental property insurance as said a clause shall be incorporated regarding the waiver of the right of subrogation towards the Landlord and/or the owners
and/or anyone acting on their behalf. 

  
 14 

	 	18.7.	The Tenant undertakes to update the insurance amounts in respect of the insurance made under clauses (1) and (4) of the Tenant’s Insurance Certificate, from time to time, so as to reflect the full value
of the insured. 

  

	 	18.8.	The Tenant exempts the Landlord and/or anyone acting on its behalf and/or the other tenants and/or lessees and/or other right holders in the real estate (provided that a parallel waiver towards the Tenant is included in
their agreements) from liability for damage for which it is entitled to indemnification in accordance with the insurance arranged under clause (1) of the Tenant’s Works Insurance Certificate and clauses (1) and (4) of the
Tenant’s Insurance Certificate (or for which it was entitled to indemnification if it had not been for the deductible amounts specified in the policies) however the said exemption from liability as said shall not apply in favor of a person who
caused willful damage. 

  

	 	18.9.	No later than expiration date of the Tenant’s insurances, the Tenant undertakes to furnish the Landlord the Tenant’s Insurance Certificate in respect of extension of the said Certificate by an additional year.
The Tenant undertakes to furnish to the Landlord the Tenant’s Insurance Certificate each insurance year and as long as this Agreement is in effect. 

  

	 	18.10.	Whenever the Tenant’s insurer notifies the Landlord that any of the Tenant’s insurances is about to expire or undergo adverse change, as specified in the final part of Appendixes 1 and 2 as said, the Tenant
undertakes to renew the said insurance and furnish a new Insurance Certificate 14 days prior to the expiration or the adverse change in the insurance as said. 

  

	 	18.11.	To dispel any doubt it is clarified that failure to furnish the Insurance Certificates on time as specified in clauses 19.1, 19.3, 19.9 and 19.20 hereinabove, shall not derogate from the Tenant’s undertakings in
accordance with this Agreement including and without derogating from the generality of the aforesaid, any payment obligation applicable to the Tenant, and the Tenant undertakes to uphold all its undertakings in accordance with this Agreement even if
implementing the works and/or receiving possession in the Leased Premises and/or bringing assets into the Leased Premises is denied from it due to failure to furnish the certificates on time. 

 

	 	18.12.	 The Landlord shall be entitled to inspect the Insurance Certificates furnished by the Tenant as specified in 19.1, 19.3, 19.9 and 19.10 hereinabove,
and the Tenant undertakes to implement any modification or amendment that is required so as to adjust the said Insurance Certificates 

  
 15 

	 	
to the Tenant’s undertakings as specified in this Agreement, and subject to obtaining the consent of the insurance company. The Tenant declares that the right of inspection of the Insurance
Certificates granted to the Landlord and the right granted to the Landlord to instruct their amendment as specified hereinabove shall not impose on the Landlord and/or anyone acting on its behalf any obligation and/or liability in anything related
to the Insurance Certificates as said, including their quality, scope and effect of the insurances arranged in accordance with the Certificates as said or regarding their absence, and it shall not derogate from any liability imposed on the Tenant in
accordance with the provisions set forth in this Agreement and/or in accordance with the provisions set forth in any law. 

  

	 	18.13.	The Tenant undertakes to uphold the provisions set forth in the insurance policies it arranges, pay insurance premiums fully and timely, and assure that the Tenant’s insurances are renewed from time to time as
needed and shall be in effect during the entire Term of Lease. 

  

	 	18.14.	The Tenant undertakes to observe the safety procedures/directions that are published (if published) by the Landlord from time to time. 

 

	 	18.15.	To dispel any doubt, it is hereby agreed that the liability limits that are required in accordance with the Insurance Certificates are a minimal requirement that is imposed on the Tenant. The Tenant declares and affirms
that it shall be precluded from raising any claim and/or demand towards the Landlord and/or anyone acting on its behalf in anything related to the liability limits as said. 

 

	 	18.16.	The Landlord shall arrange and maintain the following insurances during the entire term of the principal agreement: 

  

	 	    	Extended fire insurance, providing insurance coverage for loss or damage to the building of the Leased Premises in full reinstatement value (except for additions and alterations that were added or will be added by the
Tenant or anyone acting on its behalf) and, without derogating from the generality of the aforesaid, including against the risks covered under extended fire insurance policy including fire, smoke, explosion, storm, flood, earthquake, fluid damage,
impact by a vehicle and/or a hoisting device, riots, strikes, willful damage and burglary. The Tenant shall pay the Tenant’s share in the insurance as specified hereinabove for arranging the said insurance. 

 

	 	18.17.	The Tenant shall be entitled, however not obligated, to examine a copy of the insurance policy that was issued to the Landlord and that is kept in the offices of the Landlord, after advance coordination. The foregoing
shall not derogate from the Landlord’s obligations in accordance with this Agreement and impose on the Tenant any obligation and/or liability in connection with the Landlord’s insurances. 

  
 16 

	19.	Miscellaneous 

  

	 	19.1.	This agreement expresses everything agreed between the parties and replaces and revokes any written or oral representation or understanding that existed, if at all, between the parties on the matters mentioned herein
prior to the execution hereof. Any modification and/or amendment and/or addition to this Agreement shall be null and void unless executed in writing and signed by the parties. 

 

	 	19.2.	Any agreement or arrangement or understanding between the parties shall be null and void unless executed in writing and signed by the parties. 

 

	 	19.3.	Postponement or avoidance from exercising any right by any of the parties shall not be deemed as waiver of that party with respect to the said right unless that party waived its rights expressly and in writing.

  

	 	19.4.	In the event the Tenant comprises of two or more members, all of their undertakings towards the Landlord shall be jointly and severally. 

 

	 	19.5.	The reliefs the Landlord may seek in accordance with the provisions set forth in this Agreement and/or in accordance with the provisions set forth in any law are cumulative and not interchangeable. 

 

	 	19.6.	As of the commencement date of the lease this Agreement shall prevail over and supersede the Lease Agreement that was signed between the parties on April 18, 2002 and addenda thereof and the Management Agreement
enclosed therewith. 

  

	20.	Addresses 

  

	 	20.1.	The addresses of the parties for the purpose of this Agreement are as specified hereunder and any notice delivered by one party to the other party shall be deemed to have reached its recipient 72 hours following its
delivery in registered mail. 

  

	 	20.2.	Address of the Landlord – 1 Moshe Aviv St., Or-Yehuda Industrial Zone 60371. 

  

	 	20.3.	Address of the Tenant – during the Term of Lease – in the Leased Premises and in the address specified in the preamble to this Agreement at any other time. 

And in witness hereof the parties are hereby undersigned: 

 

					
	 /s/ Maslari Construction Co. Ltd.
	 		 	 /s/ Dror Harats

	The Landlord	 		 	The Tenant

  
 17 

 Appendix 1: Tenant’s Works Insurance Certificate 

Date:
                             

To 
 Maslavi Construction Co. Ltd. (hereinafter:
“Landlord”) 
 1 Moshe Aviv St., Or-Yehuda Industrial Zone              

Dear Sir/Madam, 
  

	 	Re:	Insurance Certificate in the name of             (hereinafter: “Tenant”), inter alia in connection with lease of a property in a
building built on land known as block             parcel             in
            (hereinafter respectively: “Leased Premises” and “The Building”) 

We hereby certify that as of             and until
            (hereinafter: “Period of Works”) and during an extended maintenance period of 12 months (the Period of Works and the maintenance period shall be referred to
hereinafter jointly: “Insurance Period”) our company arranged contractor insurance (Policy No.             ) in the name of the Tenant, contractors and subcontractors (in
any rank), and in the name of the Landlord and/or the management company of the Building (hereinafter: “Management Company”), providing insurance coverage for the works implemented by the Tenant and/or anyone acting on its behalf
(hereinafter: “Works”) as specified hereunder, when the scope of insurance coverage provided under the insurance as said shall not fall below the scope of insurance coverage provided under the policy known as “Bit 2008”
(or any “Bit” policy at the time of arranging the insurance), including all extensions constituting an inseparable part of the policy as said: 
  

	1.	 Chapter 1 – insurance for the Works, in full value (including materials provided by the Landlord and/or the Management Company) against loss or
damage caused during the period of implementing the Works in the work site and during the maintenance period for the purpose of upholding the undertakings of the Tenant during this period and/or discovery of damage during the maintenance period due
to reasons contingent on the works implementation period. This Chapter includes a clause on waiver of the right of subrogation towards anyone acting on behalf of the Landlord and/or the Management Company and towards other tenants, lessees and other
right holders in the Building (the other tenants, lessees, and right holders shall be referred to hereinafter: “Other Right Holders”) when in the property insurance of the Other Right Holders a parallel clause on waiver of the right
of subrogation towards the Tenant and/or in an agreement granting rights in the Building to the Other Right Holders is included as said and there is an exemption from liability in favor of the Tenant in respect of damage or loss caused to the
property of the Other 

  
 18 

	 	
Right Holders due to the customary risks in contractor insurance or in extended fire insurance, however the said waiver shall not apply in favor of a person who caused willful damage. In
addition, the Chapter includes express extension regarding insurance coverage to adjacent property and property under work in a liability limit of $100,000 (one hundred thousand U.S. dollars). 

 

	2.	Chapter 2 – third party liability insurance in respect of the legal liability deriving from works in a liability limit as specified hereunder. The said chapter includes a cross-liability clause according to which
the insurance is deemed to have been arranged separately for each of the members of the insured. The chapter states expressly that the Building of the Leased Premises is deemed as third party property. 

To dispel any doubt, it is clarified that the liability limit of the insurer in respect of adjacent property and property under work as
specified in Chapter 1 of the policy and in respect of Chapter 2 shall not exceed $250,000. 
 Liability limit: $1,000,000 per event and
cumulatively according to the chapter. 
 The said Chapter is extended to include the following: 

 

	 	A.	Claims of subrogation by the National Insurance Institute up to US$ 250,000 per event and in total. 

  

	 	B.	Bodily damages deriving from the use of heavy engineering equipment which is a motorized vehicle and that is not required to be insured under compulsory insurance up to an amount of $150,000. 

 

	 	C.	Liability for damage that was caused due to weakening and vibrations of foundations in a liability limit of $100,000 per event and in total. 

 

	3.	Chapter 3 – employers’ liability insurance providing insurance coverage towards any of the workers employed in the implementation of the Works in respect of a bodily damage or occupational disease that could
be caused to any of them in the course of or following their employment as said, in a liability limit of $5,000,000 per plaintiff, per event and cumulatively for the Insurance Period. This insurance does not include any limitation regarding works in
depth and in height, hours of work, baits and poisons, contractors, subcontractors and their workers in the event they are deemed as the Tenant’s workers, and youth employment in accordance with the law. In addition, the said insurance includes
waiver of the right of subrogation towards anyone acting on behalf of the Landlord and/or the Management Company, however the said waiver shall not apply in favor of a person who caused willful damage. 

The policy specified hereinabove shall prevail over any insurance arranged by the Landlord and/or the Management Company and we waive any demand and/or claim

  
 19 

 
regarding participation of the insurances of the Landlord and/or the Management Company. In addition, we undertake that the above noted policy shall not be terminated or adversely changed during
the Insurance Period unless a prior notice is delivered to the Landlord at least 30 days in advance to that effect. To dispel any doubt, we affirm that the Tenant shall be solely liable for paying the insurance premiums in respect of the said
policies and incur the deductible amount applicable in accordance with the said policy. 
 Subject to the terms and exclusions set forth in the original
policy to the extent that they were not expressly modified in accordance with the foregoing. 
 Respectfully yours, 

 

							
	  
	 	  
	 	  
	 	  

	(Stamp of Insurer)	 	(Signature of the Insurer)	 	(Name of Signatory)	 	(Position of Signatory)

  
 20 

 Appendix 2: Tenant’s Works Insurance Certificate 

Date:
                             

To 
 Maslavi Construction Co. Ltd. (hereinafter:
“Landlord”) 
 1 Moshe Aviv St., Or-Yehuda Industrial Zone              

Dear Sir/Madam, 
  

	 	Re:	Insurance Certificate in the name of             (hereinafter: “Tenant”), inter alia in connection with lease of a property in a building
built on land known as block             parcel             in
            (hereinafter respectively: “Leased Premises” and “The Building”) 

We hereby certify that as of             and until
            (hereinafter: “Insurance Period”) we arranged the insurance specified hereunder inter alia in connection with the Lease Agreement referenced hereinabove: 

 

	1.	Policy No.              

 Extended
fire insurance providing insurance coverage in full value for loss or damage to the content and/or additions and improvements that were added to the Leased Premises and/or the property by the Tenant and/or anyone acting on his behalf of any kind and
owned by the Tenant and/or under his responsibility and that is located in and/or adjacent to the Leased Premises (without derogating from the generality of the aforesaid, including furniture, equipment, facilities and inventories of any kind),
against fire, smoke, lighting, explosion, storm, flood, earthquake, fluid damage and splitting of pipes, impact by a vehicle and/or hoisting device, impact by an aircraft, riots, strikes, willful damage and burglary. The insurance includes a clause
on waiver of the right of subrogation by the insurer towards the Landlord and anyone acting on its behalf and/or towards the other tenants and/or lessees (if a parallel clause regarding waiver of the right of subrogation towards the Tenant is
included in their insurances) provided that the waiver of the right of subrogation as said shall not apply in favor of a person who caused willful damage. 
  

	2.	Policy No.              

 Third
party liability insurance in respect of liability for loss, damage or damage to the body and/or property of any person and/or entity, in a liability limit in the amount of NIS 8,000,000 in respect of one insurance event and cumulatively for an
insurance period of one year. The insurance shall not be subject to any limitation regarding: fire, explosion, panic, hoisting, loading and unloading devices, liability 

  
 21 

	 	
in respect of and towards contractors and subcontractors, defective sanitary fixtures, poisoning, anything harmful in foods and beverages, implementation of additions and improvements in the
Leased Premises, strikes and lockouts, and claims of subrogation on behalf of the National Insurance Institute. The said insurance is extended to indemnify the Landlord in respect of its liability for the acts and/or omissions of the Tenant, subject
to a cross-liability clause according to which the insurance was arranged separately for each of the members of the Insured. 

  

	3.	Policy No.              

Employers’ liability insurance in respect of the liability of the Tenant towards its employees in a liability limit of NIS
20,000,000 per plaintiff, per event and for an annual insurance period, when the insurance does not include any limitation regarding the implementation of additions and improvements in the Leased Premises, baits and poisons, and youth
employment by law. The insurance is extended to indemnify the Landlord in the event it is alleged, for the purpose of the occurrence of an accident and/or any occupational disease, that it is held liable as an employer towards any of the
Tenant’s employees. 
  

	4.	Policy No.              

Consequential loss insurance (except for rent for the Landlord) due to damage that was caused to the content of the Leased Premises and/or the
Building where the Leased Premises are located, in full value, due to the risks enumerated in clause (1) hereinabove, for an indemnification period that shall not fall below 12 months. The insurance includes a clause regarding waiver of the
insurer on the right of subrogation towards the Landlord and anyone acting on its behalf and/or towards the other lessees and/or tenants (provided that a parallel clause regarding waiver of the right of subrogation towards the Tenant is included in
their insurances) provided that the said waiver of the right of subrogation as said shall not apply in favor of a person who caused willful damage. 
 We
hereby confirm that all the insurances specified hereinabove prevail over any insurance arranged by the Landlord and that we waive any demand or claim regarding participation of the Landlord’s insurances. 

We further confirm that the above noted insurances shall not be diminished or terminated during the term of the Agreement unless we deliver to you a notice to
that effect in registered mail at least 30 days in advance. 
 Subject to the terms and exclusions of the original policy to the extent that they were not
expressly modified in accordance with the foregoing. 

  
 22 

 Respectfully yours, 
  

							
	  
	 	  
	 	  
	 	  

	(Stamp of Insurer)	 	(Signature of the Insurer)	 	(Name of Signatory)	 	(Position of Signatory)

  
 23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]